

Index

abortion services	Advanced Therapy Medicinal Products
citizens’ initiative concerning, 96n126	Regulation (1394/2007/EC), 170–6, 322–4
health rights law and, 160–4	human tissue and cells regulations, 352–8
national ethical sensitivity issues and,	medical device and products regulation and,
91–6	371–8
origins of laws on, 13–17	advance market commitments (AMC),
‘abuse of a dominant position’, competition	medicinal products development and,
law and freedom to trade decisions and,	498–501
229–35	advertising laws
access to health care	alcohol advertising and, 118
cross-border movement of goods and	dental clinics and, 262–4
services and, 101–5	e-cigarettes, 396–9
essential medicines access, 483–501	market authorization regulations on
EU citizenship and, 202–6	pharmaceuticals and, 114–16
global health law and, 433–7	for pharmaceuticals, 337–41
health law and, 24–5	risk regulation and, 424–31
health rights as human rights and, 156–60	tobacco regulations, 390–403
in-patent medicines and generics and,	advertising of pharmaceuticals, patient and
486–92	consumer protection rules and, 113–14
for mobile workers, 60–3	Advisory Committee on Medical Training,
patients’ rights and, 78–82	142–6
private individual’s litigation and, 105–8	AGR2 case, 240–1, 243–6
privatization of health services and, 451–4	Agreement on Technical Barriers to Trade
Action Plan of 2014 (European Commission),	(TBT), 451–4
418–23	essential medicines and, 483–5
‘Active Citizenship Network’, 185–9	food-related law and policy and, 523–6
Additional Protocol Convention on Human	Agreement on the Application of Sanitary and
Rights and Biomedicine concerning	Phytosanitary Measures (SPS
Transplantation of Organs and Tissues of	Agreement), 451–4, 457–63
Human Origin, 473–7	food-related law and policy and, 523–6
additives regulation	Agreement on the Trade-Related Aspects of
food regulation and, 404–8, 410–13	Intellectual Property Rights (TRIPS)
tobacco products, 396–9	counterfeit/falsified medicines and, 492–8
administrative law	food-related health laws and, 451–4
development of EU health law and, 66–7	globalization of health research and, 508
food regulation and, 404–8	health research and, 462–3
health system organization and, 219–21	in-patent and generic medicines and,
human rights constraints on, 170–6	486–92

medicinal products and vaccines	Apozyt, 346–7
development and, 498–501	<i>Aristolochia</i> (birthwort) incident, 333–4
agricultural law, mainstreaming of health	<i>Arnold André GmbH & Co. KG v. Landrat des Kreises Herford</i> , 396–9
legislation and, 30–3, 60–3	Asia, sale of human organs in, 473–7
alcohol	assisted reproduction services, national ethical
advertising for, CJEU rulings on, 118	sensitivity issues and, 91–6
assessment of regulations on, 423–4	‘association of undertakings’, competition law
EU regulatory approaches to, 387–90,	and freedom to trade decisions and,
418–23	229–35
global health perspective on, 437–43	AstraZeneca, 281–5
Alcohol (Minimum Pricing) (Scotland) Act,	asylum seekers
418–23	right to health care for, 176–7
Alemanno, A., 423–4	social security entitlements coordination
‘alert mechanism’, suspension of health	with patients’ rights and, 189–94
professionals and, 146–51	Aumaitre, Oliver, 548–50
Altenstetter, Christa, 368–78	austerity policies, impact in EU health law of,
alternative dispute resolution, risk regulation	52–3
and, 295–301	Austria
‘Altmark package’	blood and blood products regulations in,
hospital regulation and, 247–52	116–17, 363–5
medical devices and equipment regulations	dental clinics in, 262–4
and, 270–8	entry into health professions and, 142–6
‘Alumnia package’, 265–8	authoritative interpretations, CJEU case law as,
hospital regulation and, 247–52	55–9
medical devices and equipment regulations	automatic recognition principle
and, 270–8	entry into health professions and, 142–6
<i>Ambulanz Glöckner</i> case, 229–35, 243–6	suspension of health professionals and,
Amsterdam, Treaty of, coherence in EU health	146–51
law and, 40–53	autonomy
Ancient Greece, health law and ethics in, 17–19	food laws and, 414–18
animal health and slaughter standards, EU	health rights and, 156–60
trade law and, 457–63, 523–6	individual perspectives in health law and,
anti-cartel rules	71–2
competition and freedom to trade in health	judicial protection of, 160–4
systems and, 229–35	organ donation and transplantation and,
hospital regulation and, 247–52	473–7
pharmacies’ regulations and, 257–9	patients’ rights and, 78–82
pricing challenges and generic promotion,	population health and, 387–90
278–81	risk regulation and, 424–31
anti-competitive behaviour	tobacco regulation and, 399–403
justification for, 235–43	Autorité de la concurrence, 278–81
pricing challenges and generic competition	Bache, G., 363–5
promotion, 278–81	Barroso, José Manuel, 392–4
Anti-Counterfeiting Trade Agreement (ACTA),	basic hygiene, regulation of health care and,
496–8	23–4
Anti-Trafficking Convention (Council of	‘basket of care’ principle, 199–202
Europe), 473–7	dental clinics and, 262–4
antitrust regulations, competition law and	EU health law and, 538–40
freedom to trade in, 229–35	opticians and ophthalmologists and, 264–5
‘any qualified provider’ concept, hospital	<i>Beer Purity Law</i> (Germany), 116–17, 418–23
regulations and, 247–52	
AOK case, 237–40	

- behavioural guidelines
 - EU regulatory bodies and, 66–7
 - soft law mechanisms and, 59–60
- Belgium
 - entry into health professions and, 142–6
 - patients’ rights in, 185–9
 - pharmaceutical price and profit restrictions in, 119–20
- benchmark systems, soft law mechanisms and, 59–60
- Bertollino, Roberto, 392–4
- Besluit farmaceutische hulp ziekenfondsverzekering* (Sickness Insurance Fund (Provision of Medicinal Preparations) Order), 119–20
- ‘best value’ calculations, pharmaceuticals and medical device regulations and, 270–8
- BetterCare Ltd v. Director of Fair Trading*, 229–35, 243–6
- Beveridgean funding model, 220–1
- Bexero* vaccine case, 88–91
- big data, health rights as human rights and use of, 170–6
- bilateral investment treaties (BITS),
 - intellectual property rights and, 486–92
- biomedical ethics. *See* ethics
- biosimilarity principle
 - market authorization of pharmaceuticals and, 327–34
 - ‘market pathway’ model for pharmaceuticals and, 341–7
 - pharmaceuticals regulations and, 272n12
- Biotechnology Directive (1394/2007/EC),
 - human rights constraints and, 170–6, 360–1
- Bismarckian funding model, 220–1
- black market for human organs, 473–7, 481–2
- blood and blood products
 - competition law and freedom to trade concerning, 229–35
 - cross-border movement of products and services and, 100–5
 - EU law on, 23–4, 44–5, 322–4, 349–52
 - free movement of goods and services, 261–2
 - internal market strategies and, 34–40
 - patient and consumer protection rules and, 116–17
 - professional liability in contamination litigation, 22–3
 - safety regulations and, 292–5
 - voluntary and unpaid blood donations, 478–83
- Blood Safety Directive (2002/93/EC), 349–52
- ethics and human rights and, 361–5
- organ donation and transplantation and, 478–83
- voluntary/unpaid donations regulations, 361–5
- Boehringer-Ingelheim company, 490–1
- ‘Bolar exemption’, 341–7
- ‘bounded rationality’ principle, organ donation and transplantation and, 473–7
- Bowis, John, 512–17
- Brazier, M., 13–17
- breast implants case, 3–9, 36, 292–5, 548–50
- Bressol* case, 132–7
- Bretton Woods agreements, global health law and, 437–43
- ‘BRICS’ (Brazil, Russia, India, China) countries
 - counterfeit/falsified medicines and, 492–8
 - EU development initiatives and, 467–9
- Bristol-Meyers Squibb* test, 341–7
- trade-mark protections and, 108–12
- Bristol Royal Infirmary, clinical practices at, 23–4
- Bristle* case, 170–6, 352–8, 365–6
- BSE/vCJD crisis
 - EU food safety law and policy and, 408–10, 517–22, 523–6
 - EU trade law and, 457–63
 - in United Kingdom, 60–3, 65
- Bulgaria, patients’ rights in, 185–9
- Bundeskartellamt, 278–81
- BUPA Ireland* case, 237–40, 243–6
- Byrne, David, 512–17
- capitalism, continental European *versus* Anglo-Saxon versions of, 227–9
- CARIFORUM agreement
 - EU partnership with, 457–63
 - intellectual property rights and, 486–92
- case law
 - of CJEU, 55–9
 - EU health law and, 13–17, 30–3, 63–9
 - free movement of goods and services and, 194–8
 - patient and consumer protection rules and, 112–18
 - patients’ rights and, 76–83

- recent ‘restriction’ interpretations in, 83–5
- Cassis de Dijon* case, 34–40, 418–23
- CE certification mark
 - internal market strategies for EU health law and, 34–40
 - medical devices and products, 368–71
 - pharmaceuticals and medical device regulations and, 270–8
- Centers for Disease Control (CDC) (USA), 515–17
- centralization
 - administrative/legal typologies for health systems and, 219–21
 - of pharmaceutical market authorization, 327–34
- Cerezyme, regulation of, 281–5, 334–7
- Chanda, R., 457–63
- Chico, Victoria, 222–5
- children
 - Clinical Trials Directive guidelines on, 312–19
 - heart valves in, Human Tissue and Cells Directive concerning, 352–8
 - paediatric pharmaceuticals regulation and, 334–7
 - right to health care for, 176–7
- China
 - counterfeit/falsified medicines in, 492–8
 - sale of human organs in, 473–7
- Choudry, Shazia, 182
- Citizenship Directive (2004/38/EC), 132–7
- civil and political rights
 - health rights and, 156–60
 - right to health care and, 176–7
- civil litigation
 - compensation for harm from pharmaceuticals and medical devices, 379–84
 - professional liability in health law and, 22–3
- clinical trials
 - ethical issues and, 424–31
 - EU health law, 53–5, 172–6, 301–5, 320
 - global health law and, 433–43
 - globalization of health research and, 504–8
 - market authorization of pharmaceuticals and, 327–34
- Clinical Trials Coordination and Advisory Group, 305–12
- Clinical Trials Directive and Regulation, 172–6
 - assessment of, 320–1
 - current trends in, 548–50
 - ethics in, 312–19
 - evolution of, 302–5
 - market authorization of pharmaceuticals and, 327–34
 - medical device and products regulation and, 371–8
 - risk management in, 312–20, 424–31
 - scope, obligations, and responsibilities in, 305–12
- Clinique* case, 112–13, 116–17
- cloning, health rights concerning, 160–4
- ‘cluster trials’, Clinical Trials Directive guidelines for, 317–19
- codes of conduct, soft law mechanisms and, 59–60
- Codex Alimentarius Commission (CAC)
 - Agreement on the Application of Sanitary and Phytosanitary Measures and, 451–4
 - EU food safety law and policy and, 517–22
 - global health law and, 448–51
- Coggon, John, 14–15, 17–19, 433–7
- Cohen, Glenn, 473–7, 481–2
- coherence in health legislation
 - evolution of health law and, 13–17, 49–50, 69–70
 - internal market strategies and, 40–53
 - mainstreaming of EU health legislation and, 60–3
- ‘cohesion funds’, in EU health law, 49–50
- collective perspectives in healthcare law, 6–9, 540–4
- collusive practices
 - in competition and free movement law, 235–43
 - hospital regulation and, 247–52
 - industry challenges to restrictions on, 281–5
 - pharmacies regulations and, 252–9
 - pricing challenges and generic competition promotion, 278–81
- colonialism, EU development policies and, 463–9
- Comité Européen des Entreprises Vins, 418–23
- ‘comitology’ in administrative law,
 - development of EU health law and, 66–7
- commercial surrogacy, 436n34
- Commission v. France (Establishment of Doctors and Dentists)*, 132–7
- Commission v. France (Major Medical Equipment)*, 88–91

- Commission Directive 2005/28/EC, 305–12
- Commission v. Portugal (Non-hospital Medical Care)*, 83–5, 88–91
- Commission v. Spain (Emergency Hospital Care)*, 83–5, 199–202
- Committee for Herbal Medicinal Products, 333–4
- Committee for Medicinal Products for Human Use, 327–34
- Committee for Orphan Medicinal Products for Human Use, 334–7
- Committee of Experts on Trafficking in Organs, 473–7
- Common Agriculture Policy (CAP)
 - development of EU food laws and, 404–8
 - EU food-related law and policy and, 523–6
 - EU health law and, 30–3
 - tobacco regulation and, 390–403, 526–30
- common commercial policy, intellectual property rights and, 492–8
- communicable diseases
 - EU health law on, 53–5, 512–17
 - global health law and policy and, 437–43, 508–22
 - population health and, 483–5
 - public health law and, 25–6
- Community Charter on Fundamental Social Rights for Workers 1989, 40
- Community Code relating to medicinal products for human use (Directive 2001/83/EC)
 - amendments to, 114–16
 - clinical trials and, 324–7
 - market authorization of pharmaceuticals and, 327–34
 - pharmaceutical packaging, labelling and advertising and, 337–41
- community health, public health law and, 25–6
- compensating measures, entry into health professions and, 142–6
- compensation laws
 - Clinical Trials Directive and Regulation and, 312–19
 - pharmaceuticals and medical devices, harm resulting from, 379–84
 - professional liability in health law and, 22–3
- competent authority principle
 - EU communicable diseases law and, 512–17
 - EU food safety law and policy and, 517–22
 - Human Tissue and Cells Directive and, 352–8
 - medical devices and products and, 368–71
 - organ donation regulations and, 358–60, 478–83
- competing rights, health care regulations and, 170–6
- competition, health laws and
 - assessment of, 288–91
 - blood and human tissue centres, 261–2
 - continuum of health system typologies and, 222–5
 - dental clinics and, 262–4
 - equality and solidarity *versus*, 6–9, 227–9
 - EU food safety law and policy and, 517–22
 - EU health law and, 60–3, 540–4
 - freedom to trade across borders and, 227–35
 - health professionals’ relations with industry and, 285–8
 - hospitals and, 247–52
 - industry challenges to, 281–5
 - institutions and professions and, 247–65
 - laboratories regulations and, 259–61
 - managed competition, 219–21
 - ‘market pathway’ model for pharmaceuticals and, 341–7
 - opticians and ophthalmologists and, 105–8, 264–5
 - pharmacies and, 252–9
 - pricing challenges and generic competition promotion, 278–81
 - questions and answers on, 554–5
 - social *versus* private insurance and, 235–43
 - systemic focus on, 211–13
 - treaty law and, 63–9
- Competition and Markets Authority, 237
- Competition Commission, 237
- complementary private insurance
 - competition and free movement law and, 235–46
 - health professionals relations with, 285–8
- compulsory insurance, 220–1
- confidentiality
 - Data Protection Directive and, 101–5
 - in EU health legislation, 20–2, 26–7, 53–5
 - human right to, 160–4, 172–6
 - patient’s rights and, 185–9
- connective tissue, Human Tissue and Cells Directive concerning, 352–8
- consensus building
 - ethics and human rights in human materials regulation and, 361–5

legislative and judicial procedures in EU health law and, 68–9	patient and consumer protection rules and, 112–18
consent process	patients’ rights and, 85–8, 206–10
in Clinical Trials Directive and Regulation, 312–19	pharmaceutical packaging, labelling and advertising and, 337–41
data protection and privacy and, 170–6	pharmacy services and product provision, regulations involving, 120–4
ethics and human rights of human materials legislation and, 361–5	price and profit regulation, 119–20
EU health law and, 20–2, 160–4	private individual’s litigation and, 105–8
global health law and, 437–43	questions and answers on, 551–2
legal representative powers and, 316–17	recent ‘restriction’ interpretations and, 83–5
organ donation and transplantation and, 358–60, 473–7, 481–2	reimbursement restrictions and, 119–20
patient’s rights and, 185–9	risk regulation and, 298–301
constitutional framework	tobacco, food and alcohol regulation and, 423–4
administrative/legal typologies for health systems and, 219–21	contact lenses
cross-border movement of products and services, 100–5	cross-border movement of health goods and services regulations and, 101–5
ethical sensitivity issues and, 91–6	free movement and competition laws and sale of, 264–5
EU internal market strategy and, 45–50	continuum of health system typologies
European Union Charter of Fundamental Human Rights and, 164–6	Member States’ position on, 222–5
health rights and, 160–4	risk regulation and, 225–6
Constitution for Europe, Treaty for, 50–3	contraception services. <i>See also</i> reproductive rights
constrained competition in health systems, 222–5	health rights <i>versus</i> human rights and, 170–6
<i>Consumer Policy Strategy</i> , 414–18	national ethical sensitivity issues and, 91–6
consumer rights framework	contract research organizations, medical device and products regulation and, 371–8
compensation for harm from	Convention for the Protection of Human Rights and Dignity of the Human Being with regard to the Application of Biology and Medicine, 160–4
pharmaceuticals and medical devices and, 379–84	Convention on Human Rights and Biomedicine (Council of Europe), 40
competition law and, 235–43	organ donation and transplantation and, 473–7
cross-border health services and, 100–5	pharmaceutical packaging, labelling and advertising and, 337–41
EU health law and impact of, 6–9, 73–5, 96–7, 124–6, 540–4	coordinated market economies, continuum of health system typologies and, 222–5
food labelling regulations and, 410–13	copyright law, counterfeit/falsified medicines and, 492–8
free movement of goods and services and, 98–105, 235–43	core health care benefits, right to health care and, 176–7
harmonization of pharmaceutical laws and, 324–7	Corporate European Observatory, 392–4
health professionals and, 127–32, 142–54	‘corporate social responsibility’ principle, medicinal products and vaccines development and, 498–501
health rights as, 4	
intellectual property rules and, 108–12	
market authorization of pharmaceuticals and, 333–4	
‘market pathway’ model for pharmaceuticals regulation and, 341–7	
national ethical sensitivity issues and, 91–6	
objective public interest justifications and, 88–91	

- cosmetics, patient and consumer protection rules and, 112–13
- Cotonou Agreement, 463–9
- Council Conclusions on Common values and principles in European Union Health Systems, 50–3, 185–9, 202–6
- Council of Europe
 - blood and blood products donation and, 478–83
 - Convention on Human Rights and Biomedicine, 40, 185–9
 - counterfeit/falsified medicines and, 492–8
 - EU trade law and, 457–63
 - Experts Group on Health Information and, 67–8
 - global health issues and, 455–7
 - health rights and, 160–4
 - human tissue/organ law and, 6–9
 - legislative and judicial procedures for health law and, 65
 - ‘Medicrime’ Convention, 492–8
 - organ donation and transplantation and, 473–7, 482–3
 - Oviedo Convention, 361–5, 455–7
 - patients’ rights and, 185–9
- counterfeit/falsified medicines
 - EU development policy and, 469
 - external health law and, 433–7
 - global market and, 483–5, 492–8
- Court of Justice of the European Union (CJEU)
 - access to healthcare jurisprudence and, 202–6
 - alcohol regulations and, 118, 418–23
 - Anti-Counterfeiting Trade Agreement and, 496–8
 - assessment of, 544–6
 - case law of, 55–9, 445–7
 - compensation for harm from pharmaceuticals and medical products, 379–84
 - competition and freedom to trade case law and, 229–35, 265–8
 - consent focus in human materials rulings, 361–5
 - consumer rights in health care and, 73–6
 - data protection issues and, 101–5
 - dental clinics and, 262–4
 - EU health law and, 6–9, 30–3, 34–40, 45–50, 55–9, 68–9
 - European Court of Human Rights and, 455–7
 - food laws and, 404–8, 410–13, 448–51
 - free movement of goods and services and, 98–100, 179–81, 194–8, 199–202, 537–8
 - health professionals’ entry and accreditation and, 132–7, 142–6
 - hospital services and, 247–52
 - human materials regulations and, 44–5
 - human rights protections and, 156–64, 170–6
 - human tissue and cells regulations and, 352–8
 - industry challenges to pricing and, 281–5
 - intellectual property and trade-mark rules and, 108–12, 341–7
 - internal market strategies for EU health law and, 34–40
 - laboratories regulations and, 259–61
 - market authorization of pharmaceuticals and, 327–34
 - ‘market pathway’ model for pharmaceuticals regulation and, 341–7
 - national ethical sensitivity issues and, 91–6
 - objective public interest justifications and, 88–91
 - opticians and ophthalmologists regulations and, 264–5
 - paediatric pharmaceuticals and, 334–7
 - patient and consumer protection rules and, 112–18
 - patient’s rights jurisprudence and, 85–8, 184–5, 194–8
 - pending cases before, 548–50
 - pharmaceutical packaging, labelling and advertising and, 337–41
 - pharmaceuticals and medical devices and products and, 270–8
 - pharmacies’ regulations and, 252–9
 - price and profit restrictions regulation, 119–20
 - private individual’s litigation and jurisprudence of, 105–8
 - private insurance rulings by, 235–43
 - reimbursement restrictions and, 119–20
 - right to health care and, 176–7, 182–3
 - social rights and rulings by, 265–8
 - social security entitlements coordination and, 189–94, 199–202
 - Tobacco Advertising Directive rulings and, 390–403

- tobacco law and policy and, 526–30
- ‘undertaking’ concept and, 237–40
- working time for health professionals and, 140–2
- criminal liability
 - health professionals and, 127–32
 - internal EU health law and, 71–2
 - professional liability in health law and, 22–3
- Crispies law of 1890, 13–17
- Croatia, industry challenges to pricing
 - restrictions in, 281–5
- cross-border health services. *See also* patient mobility
 - applicable law for, 100–5
 - Clinical Trials Directive scope and obligations and, 305–12
 - ethical sensitivity issues and, 91–6
 - EU citizenship and access to, 202–6
 - EU health law and, 60–3, 433–7, 538–40
 - European Union Charter of Fundamental Human Rights and, 164–6
 - free movement of goods and services and, 83–5, 98–100, 194–8, 199–202
 - health professionals and, 127–37
 - insurance services and, 241–2
 - International Health Regulations and, 508–11
 - ‘market pathway’ model for pharmaceuticals regulation and, 341–7
 - medical tourism and, 437–43
 - objective public interest justifications and, 88–91
 - patients’ rights and, 85–8, 185–9, 194–8
 - pharmacy products and services and, 120–4
 - private individuals’ litigation against restrictions on, 105–8
 - professional practice guidelines in, 146–51
 - remuneration issues and, 76–83, 199–202
 - right to health care and, 176–7
 - service providers and posted workers, 137–40, 153–4
 - social security entitlements coordination and, 78–82, 189–94, 199–202
- cross-subsidization, in EU health systems, 214–15
- culture
 - alcohol regulation and, 418–23
 - EU food safety law and policy and, 517–22, 523–6
 - food regulation and, 403–4
 - health law and, 17–19
 - human materials technology and, 348–9
 - organ donation regulations and, 358–60
- currency movements
 - free movement of goods and services and patient mobility and, 194n77
 - mainstreaming of EU health law and, 60–3
- customs enforcement of intellectual property, counterfeit/falsified medicines and, 492–8
- cyclosporine, organ donation and transplantation and, 472–83
- Cyprus
 - industry challenges to pricing regulations in, 281–5
 - patients’ rights in, 185–9
- Dalli, John, 392–4
- damage compensation system
 - Clinical Trials Directive establishment of, 305–12
 - pharmaceuticals and medical devices, 379–84
- Daniels, Norman, 433–7
- Darbo* case, 410–13
- Dassonville* test, pharmacy products and services regulations and, 120–4
- data protection and privacy
 - Clinical Trials Directive scope and obligations and, 305–12
 - cross-border movement of health goods and services regulations and, 101–5
 - current trends in, 548–50
 - EU free movement law and, 60–3
 - in EU health legislation, 53–5
 - globalization of health research and, 504–8
 - human rights constraints and, 170–6
 - intellectual property rights and, 486–92
 - suspension of health professionals and, 146–51
- Data Protection Directive (95/46/EC), 101–5, 548–50
 - human rights constraints and, 170–6
 - regulation of pharmaceuticals and medical products and, 322–4
- data transparency in clinical trials, guidelines for, 319–20
- decentralization
 - administrative/legal typologies for health systems and, 219–21

- decentralization (*cont.*)
 - of medical devices and products regulation, 368–71
 - of pharmaceutical market authorization, 327–34
- decision-making autonomy
 - health law and, 20–2
 - national ethical sensitivity issues and, 91–6
- Decker* case, 75–83, 105–8, 119–20
- Declaration of Alma Ata (1978), 11–13
- Declaration of Istanbul on Organ Trafficking and Transplant, 473–7
- Declaration on the Promotion of Patients’ Rights in Europe (WHO), 185–9
- deferiprone, judicial review of, 58n192
- de la Rosa, Stephane, 206–10
- ‘demand side’ measures, pharmaceuticals regulations and, 270–8 *See also* supply and demand
- den Exter, André, 59–60, 243–6
- Denmark
 - insolvency scheme in, 257–9
 - patients’ rights in, 185–9
 - pricing challenges and generic promotion in, 278–81
- dental clinics, competition and free movement laws and, 262–4
- derogations
 - working time for health professionals and, 140–2
 - working time regulations and, 151–3
- detention centres, right to health care and conditions in, 176–7
- Deutsches Weintor* case, 170–6
- developing countries
 - essential medicines in, 483–5
 - incentives for medicine development in, 498–501
 - in-patent medicines and generics in, 486–92
 - medical tourism and, 437–43
- development policies
 - EU initiatives in, 463–9
 - global health and, 437–43
 - incentives for medicine development in global South, 498–501
 - in-patent medicines and generics and, 486–92
- ‘development risks defence’, compensation for harm and, 379–84
- DG EMPL, EU health legislation and, 64
- DG Enterprise, 64
- medicinal products and vaccines
 - development and, 498–501
- DG SANCO
 - communicable diseases law and, 512–17
 - compensation for harm from pharmaceuticals and medical devices, 379–84
 - food regulation and, 408–10
 - health law and policy under, 42–3
 - legislative and judicial procedures for health law and, 64
 - market authorization of pharmaceuticals and, 327–34
 - Member States’ collaboration with, 67–8
 - patients’ rights and, 185–9
 - tobacco law and policy and, 526–30
- Diane Blood* case. *See* *R. v. Human Fertilisation and Embryology Authority ex parte Blood*
- direct effects legislation
 - competition and equality in health systems and, 227–9
 - early EU health law and, 30–3
 - free movement of goods and services and, 105–8, 194–8
 - internal market strategies for EU health law and, 34–40
 - pharmacy products and services regulations and, 120–4
 - treaty law and, 63–9
- Directive 79/112/EC on food labelling, 410–13
- Directive 90/385/EEC on implantable medical devices, 366–7
- Directive 98/79/EC on *in vitro* diagnostic devices, 366–7
- Directive 2001/37/EC on tobacco products, 392–4
- Directive 2001/83/EC on pharmaceuticals marketing, 337–41
- Directive 2011/36/EU on human trafficking, 482–3
- Directive 2011/62/EU on falsified medicines, 492–8
- direct-to-consumer advertising, prohibition for prescription-only pharmaceuticals, 337–41
- direct-to-patient products
 - medical device and products regulation and, 371–8
 - pharmacy products and services regulations and, 120–4

- disability
 - obesity laws and, 414–18
 - right to health care and, 176–7
- disciplinary measures, professional practice
 - guidelines and, 146–51
- ‘disease mongering’, by pharmaceutical industry, 337–41
- disease surveillance
 - alcohol, tobacco and food regulations and, 387–90
 - EU communicable diseases law and, 512–17
 - global health perspective on, 437–43
 - health law and, 26–7
- disparities in health care access
 - health professionals’ mobility and, 127–32, 142–6
 - health rights and, 160–4
 - patient mobility rights and, 78–82
 - Patients’ Rights Directive and gaps in, 206–10
- Dispute Settlement Understanding, 448–54, 492–8
- Dixon, Anna, 216–18
- DocMorris* case, 120–4, 252–9
- ‘Doha Declaration’ 2001, 486–98
- drug trafficking, EU development agreements and, 467–9
- Duphar* case, 119–20
- Dupré, Catherine, 362
- ecclesiastical Canon law, origins of health laws and, 13–17
- e-cigarettes, EU regulations and, 396–9
- ECOFIN Council of Economic and Finance Ministers, EU health legislation and, 65
- E-Commerce Directive 2000/31/EC, 101–5
- economic and social rights, health rights and, 156–60
- economics and health. *See also* poverty
 - alcohol regulation and, 418–23
 - Clinical Trials Directive and Regulation and, 312–19
 - competition law and freedom to trade decisions and, 229–35
 - continuum of health system typologies and, 222–5
 - EU communicable diseases law and, 512–17
 - EU development policies and, 463–9
 - EU health law and, 49–50, 52–5
 - food regulation and, 403–18
 - global health laws and, 437–43
 - knowledge production and, 504–8
 - medical devices and products industry regulation and, 371–8
 - OECD initiatives and, 457
 - reform pressures and efficiency in healthcare following, 216–18
 - risk management and, 292–5
 - status of health professionals and, 127–32
- economies of scale
 - health professionals regulations and, 129–30, 142–55
 - laboratories regulations and, 259–61
 - patient’s rights and, 184–5
- EFTA Court
 - restrictions on medical treatment and, 83–5
 - tobacco law and policy and, 526–30
- Elchinov* case, 78, 82
- Patient’s Rights Directive and, 85–8, 199–202
- recent ‘restriction’ interpretations and, 83–5
- elderly, right to health care for, 176–7
- ‘embedded liberalism’, trade agreements and, 451–4
- embryonic stem cells, regulation of, 352–8
- emergency medical treatment
 - Clinical Trials Directive guidelines and, 317–19
 - patient mobility and sickness insurance and, 78–82
 - recent ‘restriction’ interpretations concerning, 83–5
 - social security entitlements coordination with patients’ rights and, 189–94
- emissions levels, tobacco regulation and, 399–403
- Employment, Social Policy, Health and Consumer Affairs Council (Council of Europe), 65
- employment law
 - health professionals and, 140–2
 - obesity-related discrimination and, 414–18
 - welfare policies and, 227–9
- end of life decision-making, national ethical sensitivity issues and, 91–6
- enforceable entitlements, right to health care and, 176–7
- engineering model of health, 11–13
- ‘ENVT’ (Environmental Public Health and Food Safety) committee (European Parliament), 65–6

- environmental legislation
 - EU food law and policy and, 523–6
 - EU health legislation and, 53–5
 - risk management and, 292–5
 - tobacco regulation and, 399–403
- equality in healthcare. *See also* access to health care; right to healthcare
 - competition and free movement law and, 243–6
 - in EU health law, 215–16, 540–4
 - global health law and, 433–7
 - hospitals and, 247–52
 - institutions and professions and, 247–65
 - laboratories regulations and, 259–61
 - pharmacies regulation and, 252–9
 - questions and answers on, 554–5
 - right to health care and, 176–7
 - solidarity and competition and, 6–9
 - systemic focus on healthcare and, 211–13
- ‘essential elements’, in EU development agreements, 463–9
- essential medicines. *See also* counterfeit/falsified medicines
 - access to, 483–501
 - counterfeit/falsified medicines and, 492–8
 - EU development initiatives and, 469
 - global health law and, 433–7
 - global market and, 437–43
 - incentives for medicine development in global South and, 498–501
- Estée Lauder Clinique case, 112–13
- Estonia, patients’ rights in, 185–9
- ethics
 - access to essential medicines and, 483–5
 - in Clinical Trials Directive, 305–19
 - clinical trials regulation and, 302–5
 - in EU health law, 17–19, 40–53, 537–8
 - food laws and, 414–18
 - global health law and, 433–43
 - globalization of health research and, 504–8
 - health rights and, 160–4
 - human materials regulations and, 360–6
 - internal market strategies for EU health law and, 34–40
 - laboratories regulations and, 259–61
 - mobility of health professionals and, 142–6
 - national ethical oversensitivity issues and, 91–6
 - organ donation and transplantation and, 472–83
 - paediatric pharmaceuticals and, 334–7
 - pharmacy services and products regulations and, 120–4
 - risk regulation and, 424–31
- EU citizenship
 - access to health care and, 202–6, 540–4
 - patient’s rights and concept of, 184–5
 - social security entitlements coordination with patients’ rights and, 189–94
- EU development policies
 - global health and, 463–9
 - medicinal product development and, 498–501
- EU employment law, health professionals and, 140–2
- EU food law and policy
 - assessment of, 517–22
 - global health and, 523–6
- EU health law
 - access to health care and, 24–5
 - assessment in existing literature of, 544–6
 - cartography of, 535–6
 - coherence in, 40–53
 - communicable diseases law, 53–5, 512–17
 - competent authority principle and, 44–5
 - competition and free movement regulations in, 288–91
 - in context, 538–40
 - countervailing elements of, 83–96
 - development of, 10
 - ethics and, 17–19
 - funding of health care services and, 24–5
 - future potential of, 546–8
 - global perspectives in, 437–43
 - hard and soft law interactions in, 68–9
 - health professionals regulation in, 53–5, 127–32, 142–54
 - history of, 30–53
 - human rights and, 20–2
 - internal and external health law and, 6–9
 - legislation and treaty provisions concerning, 53–5
 - legislative and judicial procedures for, 63–9
 - mainstreaming of, 60–3
 - national authority *versus*, 4–5
 - objective public interest justifications and, 88–91
 - organ donation and transplantation and, 358–60, 478–83
 - origins and evolution of, 13–17
 - patient and consumer protection rules and, 112–18

- professional liability in, 22–3
- public health and, 25–6
- regulation of health care in, 23–4
- right to health care development in, 160–9
- risk focus in, 295–301, 424–31
- scope of legislation, 19–28, 42–3, 53–5, 60–3
- soft law and, 59–60, 63–9
- sources of, 53–60
- table of instruments, legislation and agreement, xxxviii–lxi
- taxonomy for, 537
- EU Health Policy Forum, 43n94
 - legislative and judicial procedures for health law and, 64
- Eurim-Pharm GmbH, 113–14
- ‘Eurohealth’ plan, development of, 508–11
- Europa Public Health website, 349–52
- Europe 2020 strategy*
 - Common values and principles* initiative and, 50–3
 - EU food safety law and policy and, 517–22
 - EU health law and, 45–50
 - ‘European Platform Against Poverty’ and, 67–8
 - health professionals regulation and, 142
 - ‘Europe against Cancer’ programme, 390–403
- European Accreditation Council for Continuing Medical Education, 146–51
- European Alcohol and Health Forum, 418–23
- European Centre for Communicable Disease Control (ECDC), 498–501
 - communicable diseases law and, 512–17
 - development of EU health legislation and, 66–7
- European Centre for Disease Prevention and Control, 448–51
- ‘European citizens’ initiative’, 64n218
- European Commission
 - Accountability Report, 498–501
 - alcohol regulation and, 418–23
 - blood safety and, 349–52
 - Common Values and Principles in European Union Health Systems* and, 50–3
 - competition law and freedom to trade decisions, 229–35
 - complementary private insurance and, 237–40
 - counterfeit/falsified medicines and, 492–8, 504–8
 - delayed entry of generic products and, 281–5
 - ‘development risks defence’ and, 379–84
 - EU communicable diseases law and, 512–17
 - EU food safety law and policy and, 517–22
 - EU health law and, 6–9, 42–3, 55–9
 - ‘European Health Insurance Card’ and, 189–94
 - EU trade law and, 457–63
 - food safety and, 408–10
 - health professionals regulation and, 142
 - human rights and, 156–60
 - internal market strategies and, 34–6, 40
 - laboratories regulations and, 259–61
 - legislative and judicial procedures for health law and, 64
 - litigation brought by, 108–24
 - market authorization of pharmaceuticals and, 327–34
 - ‘market pathway’ model for pharmaceuticals and, 341–7
 - medical devices and products regulation and, 371–8
 - national institutions and, 68–9
 - obesity laws and, 414–18
 - pharmaceutical price and profit restrictions and, 119–20
 - pharmacies regulations and, 120–4, 252–9
 - risk regulation and, 295–301
 - ‘smart regulation’ agenda, 45–50
 - tobacco regulation and, 392–4
 - Transparency Directive of, 270–8
 - working time regulations and, 151–3
- European Committee of Social Rights, 160–4
- European Convention on Human Rights and Fundamental Freedoms (ECHR), 30–3, 156–60
 - health rights as human rights and, 160–4
 - human materials regulations and, 360–1
- European Court of Human Rights (ECtHR), 160–4, 170–6
 - Court of Justice of the European Union and, 455–7
 - health technologies and right to life applications and, 170–6
 - human materials regulations and, 361–5
- European Development Fund, 463–9
- European Directorate for the Quality of Medicines and Healthcare, 492–8
- European Economic and Social Committee, 185–9
- European Economic Area (EEA)
 - restrictions on medical treatment and, 83–5
 - tobacco law and policy and, 526–30

- European Economic Community (EEC)
 - establishment of, 508–11
 - food laws in, 404–8
 - health law in, 30–3
- European Federation of Pharmaceutical Industries and Associations, 119–20
- European Food Safety Authority (EFSA), 404–8, 414–18, 517–22
 - development of EU health legislation and, 66–7
 - establishment of, 408–10
- European Group on Ethics in Science and New Technologies (EGE), 298–301, 424–31
- Clinical Trials Directive guidelines and, 312–19
- coherence in EU health law on, 40–53
- guidelines issued by, 67–8
- ‘European Health Insurance Card’, 189–94
- European Journal of Health Law* journal, 15–17
- European Medicines Agency (EMA)
 - CJEU case law and, 58–9
 - Clinical Trials Directive and, 305–12
 - counterfeit/falsified medicines and, 492–8
 - EU food safety law and policy and, 517–22
 - EU health law and, 66–7
 - ICH guidelines and, 455
 - market authorization for pharmaceuticals and, 327–34
 - medical devices and products and, 371–8
 - orphan drugs and, 334–7
 - paediatric pharmaceuticals and, 334–7
 - risk regulation and, 424–31
- European Medicines Agency (European Medicines Evaluation Agency), 39–40
- European Medicines Evaluation Agency, 327–34
- European Ombudsman, 424–31
 - tobacco regulation and, 392–4
- European Parliament
 - customs enforcement of intellectual property and, 492–8
 - EU development strategies and, 463–9
 - EU health law and, 6–9, 42–3, 63–6, 69
 - EU trade law and, 457–63
 - food industry lobby and, 417–18
 - medical device regulation and, 366–7
 - national institutions and, 68–9
- European Patent Convention, 355n66
- European Pharmacopoeia, 457–63
- ‘European Platform Against Poverty’, 67–8
- ‘European reference networks’, health professionals and, 129–30
- ‘European Research Area’, 320–1, 504–8
 - clinical trials regulation and, 302–5
 - creation of, 49–50
- European Research Council, 67–8
- European Social Charter (ESC), 156–60
 - health rights and, 160–4
- European Spirits Association, 418–23
- European Union (EU)
 - Council of Europe and, 455–7
 - global health and role of, 443–4, 530–2
 - health systems differences in, 218–26
 - health systems similarities in, 213–18
 - human rights in, 156–60
 - ‘knowledge production’ and, 503–4
 - World Trade Organization and, 451–4
- European Union Charter of Fundamental Human Rights (EU CFR), 20–2, 40, 156–60
 - access to healthcare and EU citizenship in, 202–6
 - Clinical Trials Directive guidelines and, 312–19
 - coherence in EU health law and, 40–53
 - competing rights and, 170–6
 - consent focus in human materials regulations and, 361–5
 - Council of Europe and, 455–7
 - global health and, 445–7, 448–51
 - health rights in, 164–6
 - medical technology constraints and, 170–6
 - non-commodification of human body and, 182
 - obesity laws and, 414–18
 - organ donation and transplantation and, 478–83
 - patients’ rights and, 185–9
 - pharmaceutical packaging, labelling and advertising and, 337–41
 - restrictions on free movement and, 179–81
 - right to health care and, 176–7
- Eurozone crisis
 - coherence in EU health law and, 52–3
 - mobility of health professionals and, 142–6
 - pharmaceutical price and profit restrictions and, 119–20
 - reform pressures and efficiency in healthcare following, 216–18
- ‘The EU Role in Global Health’, 445–7, 469–71, 508

EU trade law	Field, Mark, 219–21
Anti-Counterfeiting Trade Agreement and, 496–8	financial incentives, EU health legislation and, 66–7
EU development initiatives and, 469	Fineman, Martha, 11–13
global health and, 457–63	Finland
in-patent medicines and generics and, 486–92	entry into health professions in, 142–6
Evans Medical, 270–8	patients’ rights in, 185–9
‘evergreen’ patents, 437–43	pricing challenges and generic promotion in, 278–81
harmonization of pharmaceutical laws and, 324–7	first generation trade agreements, 462n108, 463–9
exclusive distribution schemes	Fleat, Mark, 295–301, 302n57, 348–9, 365–6, 433–7, 503–4, 507
challenges to, 278–81	Flood, Colleen, 219–21
generic products entry and, 281–5	Food and Agriculture Office (FAO)
Executive Agency for Health and Consumers, EU public health programmes and, 67–8	EU food safety law and policy and, 517–22
exhaustive harmonization	global health law and, 448–51
assessment of EU approach to, 384–6	food-related health concerns
pharmaceutical advertising regulations and, 337–41	Agreement on the Application of Sanitary and Phytosanitary Measures and, 451–4
scope of pharmaceuticals law and, 324–7	alcohol regulation and, 418–23
experimental procedures, health law and, 26–7	assessment of regulations and, 423–4
Experts Group on Health Information, 67–8	development of EU food laws and, 404–8
external health law	EU food safety law and policy and, 517–22, 523–6
assessment of, 469–71	in EU health law, 30–3, 60–3, 387–90, 403–18
EU development initiatives and, 463–9	EU non-regulatory bodies and, 67–8
EU health law and, 6–9, 53–5, 127–32, 445–7	EU trade law and, 457–63
EU trade law and, 457–63	genetically modified organisms, 523–6
future potential of, 546–8	global health perspective on, 437–43, 522–30
global market and, 501–2	harmonization of pharmaceutical laws and, 324–7
organ donation and transplantation and, 482–3	international organizations and, 448–51
overview of, 433–7	labelling laws and, 410–13
tobacco law and policy and, 526–30	nutritional claims in labelling, competing rights concerning, 170–6
extracellular matrix component, Human Tissue and Cells Directive concerning, 352–8	obesity laws and, 414–18
‘factors of production’, global health and, 530–2	patient and consumer protection laws and, 116–17
‘fair benefits’ concept, clinical trials, 437–43	pharmaceutical packaging, labelling and advertising and, 337–41
fair competition, EU legislative focus on, 53–5	risk management and, 292–5
family law	safety issues and, 408–10
EU health rights and, 182	Food Safety Regulation 178/2002/EC, 408–10
health law and, 20–2	food labelling regulations and, 410–13
Farrell, Anne Maree, 295–301, 349–52, 360–1, 363–5, 482–3	foreign investment, intellectual property rights and, 489n97
FENIN case, 281–5	‘forum shopping’, ‘market pathway’ model for pharmaceuticals and, 341–7
fertility treatments	Foster, Charles, 11–13
commercial surrogacy and, 435–6n34	
ethical sensitivity issues and, 91–6	

- fourth generation trade agreements, 457–63
 - Framework Convention on Tobacco Control, 448–51, 526–30
 - ‘Framework Programmes’ for research
 - EU trade agreements and, 462–3
 - globalization of health research and, 508
 - internal market strategies for EU health law and, 34–40
 - legal framework for, 67–8
 - France
 - entry into health professions in, 142–6
 - health insurance framework in, 240–1
 - health professionals relations with industry in, 285–8
 - laboratories regulations in, 259–61
 - patients’ rights in, 185–9
 - pricing challenges and generic promotion in, 278–81
 - fraud and abuse, Poly Implant Prothèse case and, 3–9
 - freedom of establishment principle
 - internal market strategies for EU health law and, 34–40
 - pharmacies regulation and, 252–9
 - self-employed and employed health professionals and, 132–7
 - social security entitlements coordination with, 76–83, 184–5, 189–94
 - ‘freedom of the arts and sciences’, human rights constraints and, 170–6
 - freedom to conduct business principle, human rights *versus*, 170–6
 - Freeman, Michael, 433–7
 - free movement of goods and services
 - applicable law for, 100–5
 - assessment of regulations, 288–91
 - blood and human tissue centres, 261–2
 - CJEU case law and, 55–9, 76–83
 - competition law and, 235–43
 - consumer rights perspective on, 98–100
 - counterfeit/falsified medicines and, 492–8
 - dental clinics and, 262–4
 - entry into health professions and, 142–6
 - EU communicable diseases law and, 512–17
 - EU food safety law and policy and, 517–22
 - EU health law and, 53–5, 60–3, 537–8
 - EU trade law and, 457–63
 - external health law and, 433–7
 - food labelling regulations and, 410–13
 - freedom to trade across borders and, 227–9
 - global health and, 437–43, 530–2
 - health professionals and, 127–32
 - hospital regulations and, 247–52
 - human materials regulations and, 44–5
 - intellectual property rules and, 108–12
 - internal market strategies for EU health law and, 34–40
 - justification for restrictions on, 179–81
 - laboratories regulations and, 259–61
 - legislative and judicial procedures in laws pertaining to, 63–9
 - medical devices and products and, 270–8
 - national ethical sensitivity issues and, 91–6
 - national *versus* EU decision-making on public health and, 423–4
 - objective public interest justifications and, 88–91
 - opticians and ophthalmologists and, 105–8, 264–5
 - patient and consumer protection rules and, 112–18
 - patients’ rights and, 194–8
 - pharmaceutical products and services
 - regulations and, 120–4, 270–8
 - pharmacies’ regulations and, 252–9
 - private individual’s litigation and jurisprudence of, 105–8
 - right to health care and, 159–64
 - service providers and posted workers, regulations concerning, 137–40
 - social security entitlements coordination with, 78–82, 199–202
 - World Trade Organization and, 451–4
- free movement of patients. *See also* patient mobility
- free trade preferences
 - competition law and, 229–35
 - EU food safety law and policy and, 517–22
 - EU health law and, 227–9
 - EU trade law and global health, 457–63
 - food laws and, 404–8
 - global health and, 530–2
 - global markets and, 437–43
 - in-patent medicines and generics and, 486–92
 - International Health Regulations and, 508–11
 - ‘market pathway’ model for pharmaceuticals regulation and, 341–7
 - public health regulations and, 423–4
 - risk regulation and, 298–301
 - social *versus* private insurance and, 235–43
 - tobacco law and policy and, 526–30

- Fundamental Rights Agency (FRA) (EU),
 - 166–9
 - access to healthcare and EU citizenship and, 203n143
 - right to health care and, 176–7, 182–3
- funding of health care services
 - health law and, 24–5
 - typologies for, 220–1
- Garde, A., 423–4
- Gates Foundation, 492–8
- General Agreement on Tariffs and Trade (GATT), 437–43, 451–4
 - tobacco law and policy and, 526–30
- General Agreement on Trade in Services (GATS), 437–43, 451–4
 - EU trade law and, 457–63
- General Medical Council (UK), 23–4
- generic medicines. *See also* in-patent medicines
 - access to, 486–92
 - advertising regulations for, 337–41
 - counterfeit/falsified medicines regulation
 - and suppression of, 492–8
 - market authorization for, 327–34, 341–7
 - ‘market pathway’ model for pharmaceuticals and, 341–7
 - pharmacy products and services restrictions and, 120–4
 - promotion of, 278–81, 288–91
 - regulations on, 270–8
- Generics Ltd, 270–8
- genetically modified organisms
 - development of EU health law concerning, 66–7
 - EU food law and policy and, 523–6
 - risk management and, 292–5
- genetic information and testing
 - health law and, 20–2
 - health rights and, 160–4
 - laboratories regulations and, 259–61
 - medical device and products regulation and, 371–8
- Geraets-Smits* case, 78, 199–202
- German Competition Authority (*Bundeskartellamt*), 247–52
- German Product Liability Act, 379–84
- Germany
 - alcohol regulation in, 418–23
 - compensation for harm from
 - pharmaceuticals and medical products in, 379–84
 - competition laws and hospitals in, 247–52
 - cosmetics products rules in, 112–13
 - laboratories regulations in, 259–61
 - market authorization regulations in, 114–16
 - origins of health laws in, 13–17
 - pharmaceuticals advertising in, 113–14
 - pharmacies regulations in, 252–9
 - pharmacy products and services regulations in, 120–4
 - pricing challenges and generic promotion in, 278–81
 - substitutive private health insurance in, 237–40
- Giesen, Dieter, 15–17
- The Gift Relationship* (Titmuss), 478–83
- Gilmore, Anna, 391–2
- Glaxo company, 278–81
- Global Alliance for Vaccines and Immunisation (GAVI), 491–2, 498–501
- Global Cooperation Group (GCG) (ICH), 455
- Global Europe* strategy, 457–69
 - in-patent medicines and generics and, 486–92
- Global Fund to fight HIV/AIDS, Tuberculosis and Malaria (ATM), 491–8
- Global Harmonization Task Force (GHTF),
 - medical device and products regulation and, 371–8
- global health law
 - assessment of, 530–2
 - EU health law and, 433–7, 443–4
 - EU tobacco law and policy and, 526–30
 - EU trade law and, 457–63
 - food and tobacco laws, 522–30
 - health research and, 504–8
 - international organizations and, 447–57
- global market
 - EU employment and growth and, 503–4
 - EU food safety law and policy and, 517–22
 - ‘European values’ in, 501–2
 - external health law and, 433–7
 - food regulation and, 403–4
 - health products in, 5–6, 504–8
 - health services in, 437–43, 504–8
 - incentives for medicine development in
 - global South, 498–501
 - knowledge production and, 504–8
 - national ethical oversensitivity issues and, 94–6

- global market (*cont.*)
 - organ donation and transplantation in, 358–60, 362, 472–83
 - risk regulation and, 424–31
 - tobacco regulations and, 390–403
- Global Pharma Health Fund (GPHF), 493n123
- Goldacre, Ben, 424–31
- good practices guidelines
 - in Clinical Trials Directive, 305–12
 - EU health law and, 538–40
 - health professionals and, 146–51
 - soft law mechanisms and, 59–60
- Google Spain* case, 548–50
- Gornall, Jonathan, 418–23
- Gostin, Lawrence, 433–7
- governance instruments
 - Clinical Trials Directive and Regulation and, 312–19
 - EU health legislation, 59–60, 535–6
 - hybrid legal arrangements and, 68–9
 - international law and, 445–7
- Gragl, Paul, 455–7
- Gray, David, 153–4
- Greece
 - austerity impact on healthcare in, 52–3
 - pharmaceutical price and profit restrictions in, 119–20
- Greer, Scott, 52–3, 159–60, 515–17
- Grogan* case, 60–3, 91–6, 160–4
- growth hormone, EU ban on, 298–301
- Grubb, Andrew, 15–17
- Gullung* case, 132–7
- Guy, Mary, 243–6
- H1N1 outbreak
 - European Centre for Communicable Disease Control and, 512–17
 - International Health Regulations and, 508–11
- H5N1 outbreak, 512–17
- haemophiliacs, HIV-infected blood
 - transfusions in, 349–52
- Hall, Peter, 222–5
- Hancher, Leigh, 108–12, 237–40, 243–6, 265–8, 281–5, 341–7
- Handbuch des Arztrechts* (Laufs and Uhlenbruck), 15–17
- harmonization strategies
 - blood and blood products regulations and, 116–17
 - data protection and privacy, 170–6
 - EU communicable diseases law, 512–17
 - in EU pharmaceuticals law, 324–7
 - EU trade law, 457–63
- globalization of health research and, 504–8
- global market forces and, 455
- intellectual property law, 486–92
- medical device and products regulation and, 371–8
- patient and consumer protections and, 114–16
- social security entitlements coordination and, 199–202
- Hartlauer* case, 262–4
- Hartlev, Mette, 15–17
- Hatzopoulos, Vassilis, 229–35
- health, definitions of, 11–13
- health care services. *See also* cross-border
 - health services; medical devices and product; physicians; specific services, e.g. pharmacies
 - administrative/legal typologies for, 219–21
 - competition and free movement law and, 235–43
 - continuum of systems for, 222–5
 - cross-border movement of, laws concerning, 100–5
 - in EU health law, 20, 30–3, 40–53, 124–6
 - free movement of goods and services and, 98–100
 - funding of, 24–5
 - generic products entry and, 281–5
 - international trade agreements and, 451–4
 - litigation brought by providers of, 108–24
 - organization of, 53–5
 - patient and consumer protection rules and, 112–18
 - posted workers, regulations involving, 137–40, 153–4
 - private individuals’ litigation against, 105–8
 - privatization in Member States of, 451–4
 - professional liability in health law and, 22–3
 - risk regulation in, 225–6
 - systemic focus on, 211–13
 - trade agreements and, 451–4
- ‘Health for Growth’ initiative, 49–50
- health insurance
 - administrative/legal typologies for, 219–21
 - competition law and freedom to trade decisions and, 235–43
 - cross-border movement of health goods and services and, 101–5
 - equality and competition in, 227–9
 - national policies concerning, 243–6

- Health Law*, 15–17
- Health Organization of the League of Nations (HOLN), 508–11
- health policy organizations, CJEU case law and, 55–9
- health professionals
 - CJEU case law concerning qualifications of, 55–9, 105–8
 - classification of, 127–32
 - clinical trial assessment by, 312–19
 - competition, solidarity and equality and, 247–65
 - entry rules for, 142–6
 - EU employment law and, 140–2
 - EU health law and, 53–5, 132–54
 - EU trade law and, 457–63
 - industry relations with, 285–8
 - influence of pharmaceutical industry on, 337–41
 - licensing issues, 23–4
 - pharmacies regulation and, 252–9
 - practice guidelines and, 146–51
 - qualifications and practice legislation, 60–3
 - self-employed and employed practitioners, 132–7
 - service providers and posted workers, 137–40, 153–4
 - working time legislation and, 140–2, 151–3
- health promotion and protection
 - essential medicines and, 483–5
 - food laws and, 404–8
 - global market and, 503–4
 - scope of EU health law on, 42–3
- health research
 - assessment of EU laws concerning, 320–1
 - CJEU case law on, 58n193
 - Clinical Trials Directive and Regulation and, 312–19
 - drug trials, EU focus on, 53–5
 - EU trade agreements and, 457–63
 - globalization of, 504–8
 - health law and, 26–7
 - health rights as human rights and, 160–4, 170–6
 - internal market strategies for EU health law and, 34–40
 - medicinal products development and, 498–501
 - ‘supplementary patent certificate’ and, 341–7
 - health rights. *See* access to health care; right to health care
- Health Service Executive, pharmacies’ regulations and, 252–9
- health technology. *See also* human materials; human tissue specific technologies, blood and blood products
 - assessment of EU approach to, 384–6
 - CJEU case law concerning, 55–9
 - CJEU judicial review of, 170–6
 - Clinical Trials Directive guidelines on, 312–19
 - cross-border movement of products and services and, 100–5
 - development, authorization and marketing regulations, 60–3
 - EU assessment of, 303n59
 - EU employment and growth and, 503–4
 - EU trade agreements and, 457–63
 - genetically modified food products and, 523–6
 - global market and, 437–43, 504–8
 - health rights and, 160–4
 - knowledge production and, 504–8
 - organ donation and transplantation and, 472–83
 - overview of EU regulation of, 322–4
 - risk regulation and, 295–301, 348–9
- health tourism, global perspectives in health and, 437–43
- Healy, David, 337–41
- Helsinki Declaration, health law and, 26–7
- herbal products
 - market authorization of pharmaceuticals and, 333–4
 - smoking products, 396–9
- Herring, Jonathan, 11–13
- Hervey, Tamara, 59–60, 69–70, 222–5, 295–301, 348–9
- High Level Group on Health Services and Medical Care, 67–8
- High Level Group on Innovation and Provision of Medicines, 45–50
- High Level Group on Nutrition and Physical Activity, 414–18
- Hippocratic Oath, 17–19
- HIV/AIDS
 - clinical trials of mother-to-baby transmission, 437–43
- HIV-infected blood transfusions, 349–52, 478–83

- HIV/AIDS (*cont.*)
 - International Health Regulations and, 508–11
 - international organizations and, 448–51
 - time-limited donations of medicines for, 490–1
- Hodges, C., 371–8
- Holmes, Oliver Wendell, 11–13
- Holocaust, health rights and, 156–60
- homeopathic products
 - health professionals’ use of, 285–8
 - market authorization of pharmaceuticals and, 327–34
- ‘home state control’ principle, competition and free movement law and, 235–43
- home state reimbursements by Member States
 - free movement of goods and services and, 194–8
 - health professionals mobility and, 132–42
 - patient mobility rights and, 78–82
 - Patient’s Rights Directive and, 85–8
 - private individual’s litigation and, 105–8
 - recent ‘restriction’ interpretations and, 83–5
 - social security entitlements coordination with patients’ rights and, 189–94
- homograft heart valve, EU regulation of, 352–8
- Hoppe, Nils, 352–8
- ‘Horizon 2020’ programme, 49–50
- hospital services
 - competition, solidarity and equality and regulation of, 247–52
 - in continuum of health system typologies, 222–5
 - EU trade law and, 457–63
 - globalization of, 437–43
 - objective public interest justifications and, 88–91
 - patient mobility rights and, 78n30, 198
 - pharmacy products and services regulations and, 120–4
- human dignity
 - biotechnology regulations and, 170–6
 - Clinical Trials Directive guidelines and, 312–19
 - EU health law and, 71–2
 - human materials regulations and, 40
 - human rights legislation and, 160–4
 - Human Tissue and Cells Directive and, 352–8
 - non-commodification of human body and, 361–5
 - objective public interest justifications and, 94–6
 - organ donation and transplantation and, 473–7
 - patient’s rights and, 185–9
 - restrictions on free movement and, 179–81
 - right to health care and, 164–6
- human embryos. *See also* stem cells
 - EU health laws concerning, 40
 - human rights constraints on use of, 170–6
 - Human Tissue and Cells Directive and, 352–8
 - national ethical sensitivity issues and, 91–6
- Human Fertilisation and Embryology Authority (UK), 91–6
- human materials. *See also* blood and blood products; human tissue; organ donation and transplantation; stem cells
 - assessment of EU regulations concerning, 322–4, 384–6
 - ethics and human rights issues and, 360–6
 - EU law on, 27–8, 44–5, 322–4, 349–66
 - EU trade law and, 457–63
 - free movement of goods and services and, 100–5, 261–2
 - global health law and, 433–7
 - human and health rights concerning, 160–4, 170–6, 182
 - patient and consumer protection rules and, 116–17
- Human Organ Transplantation Act (India), 473–7
- Humanplasma* case, 116–17, 363–5
- human rights
 - access to healthcare and EU citizenship and, 202–6
 - alcohol advertising regulations and, 118
 - in Clinical Trials Directive, 312–19
 - competing rights and, 170–6
 - Council of Europe and, 455–7
 - development of health rights in EU law and, 160–9
 - equality in health systems and, 215–16
 - in EU health law, 6–9, 20–2, 40–53, 540–4, 552–4
 - food laws and, 404–8
 - global health law and, 433–43
 - human materials regulations and, 360–6
 - indirect effects on health rights of, 182
 - individual perspectives in health law and, 71–2

- internal market strategies for EU health law and, 40
- mainstreaming of health legislation and, 60–3
- obesity laws and, 414–18
- organ donation and transplantation and, 473–7
- patient’s rights and, 184–5
- public health law and, 25–6
- restrictions on free movement and, 179–81
- right to healthcare as, 4, 156–60, 169–82
- risk regulation and, 424–31
- suspension of health professionals and, 146–51
- human tissue
 - cross-border movement of products and services and, 100–5
 - EU regulation of, 44–5, 322–4, 352–8
 - free movement of goods and services and, 261–2
 - health law and, 27–8
 - human and health rights concerning, 160–4, 170–6, 182
 - overview of EU regulation of, 322–4
 - patient and consumer protection rules and, 116–17
- Human Tissue and Cells Directive (2004/23/EC), 352–8, 360–1
 - medical device and products regulation and, 371–8
 - organ donation and transplantation and, 478–83
 - voluntary/unpaid donations and, 361–5
- Hungary
 - patients’ rights in, 185–9
 - pricing challenges and generic promotion in, 278–81
- hybrid legal arrangements
 - EU health law and, 68–9
 - funding typologies for health systems and, 220–1
- IMCO (Internal Market and Consumer Protection) Committee (European Parliament), 65–6
- immunization
 - compensation for harm from pharmaceuticals and medical products and, 380n244
 - development funding for, 490–1
 - ECDC initiatives for, 512–17
 - health law and, 26–7
 - market incentives for vaccine development and, 498–501
 - objective public interest justifications and, 88–91
 - pricing challenges and generic competition promotion, 278–81
- immunosuppressant pharmaceuticals, organ donation and transplantation and, 472–83
- implantable medical devices, regulation of, 366–7, 371–8
- import controls, EU food safety law and policy and, 517–22
- incentives
 - Clinical Trials Directive guidelines on, 317–19
 - consumer framework in health law and, 129–30
 - EU health law regulation of, 66–7
 - for medicine development in global South, 498–501
 - pharmaceuticals and medical device equipment market, 270–8
 - in soft law provisions, 68–9
- indemnification system, Clinical Trials Directive establishment of, 305–12
- India
 - EU trade agreement with, 457–63, 467–9
 - patent protection in, 486–92
 - sale of human organs in, 473–7
- indirect effects
 - in early EU health law, 30–3
 - of EU regulatory agencies, 66–7
 - pharmacy products and services regulations and, 120–4
 - of right to health care, 182
- individual autonomy, health rights and, 156–60
- individual perspectives in healthcare law, 6–9, 71–2, 540–4
- Indonesia, tobacco law and policy and, 526–30
- infant formula, pharmacy services and products regulations and, 120–4
- infectious disease. *See* communicable diseases
- influenza outbreaks, ECDC initiatives and, 512–17

- informational rights, 160–4
 - data protection and privacy and, 170–6
 - data transparency in clinical trials and, 319–20
 - health law and, 20–2, 26–7
 - in human materials legislation, 361–5
 - medical device and products regulation and, 371–8
 - national ethical sensitivity issues and, 91–6
 - patients' rights and, 185–9, 206–10
 - pharmaceutical packaging, labelling and advertising and, 337–41
- information sources
 - anti-competition laws and, 247–52
 - Clinical Trials Directive scope and obligations and, 305–12
 - cross-border movement of health goods and services regulations and, 101–5
 - EU communicable diseases policies and, 512–17
 - health professionals' mobility and, 127–32
 - market authorization of pharmaceuticals and, 327–34
 - pharmaceutical packaging, labelling and advertising, 337–41
 - risk regulation and, 424–31
 - soft law and, 59–60
- informed consent. *See* consent process
- 'infranationalism', development of EU health law and, 66–7
- Inizan* case, 199–202
- in-patent medicines
 - cost of, 483–5
 - global market and, 437–43
 - intellectual property law and access to, 433–7, 486–92
 - risk regulation and, 424–31
- institutional health services
 - administrative/legal typologies for, 219–21
 - competition, solidarity and equality in, 247–68
 - in EU health legislation, 53–5, 538–44
 - global health law and, 433–7, 447–57
 - human rights violations and, 170–6
 - individual perspectives in health law and, 71–2
 - judicial review of, 55–9
 - professional liability in health law and, 22–3
 - regulation of, 23–4
 - systemic focus on, 211–13
- instruments and legislation
 - EU instruments, legislation and agreement, xxxviii–lxi
 - international instruments, lxi–lxiii
 - national legislation, table, lxiii
 - table of, xxxviii
- intellectual property law
 - barriers to generic products using, 281–5
 - customs enforcement of, 492–8
 - EU health legislation on, 53–5
 - generic medicines and, 486–92
 - global health law and, 433–7
 - globalization of health research and, 504–8
 - health care products and pharmaceuticals industries and, 108–12
 - in-patent medicines and, 433–7, 483–5, 486–92
 - 'market pathway' for pharmaceuticals and, 341–7
 - Member States preferences concerning, 65
 - pharmacy products and services restrictions and, 120–4
 - risk regulation and, 295–301
- Intelligent Manufacturing Systems Initiative, 462–3
- intergovernmental organizations, global health law and, 448–51
- inter-institutional agreements, legislative and judicial procedures in EU health law and, 68–9
- internal health law
 - EU health legislation and, 6–9, 53–5, 127–32, 540–4
 - right to health care and, 182–3
 - risk focus in, 424–31
 - systemic focus on, 211–13
 - tobacco law and policy and, 526–30
- internal markets policies
 - administrative/legal typologies for health systems and, 219–21
 - CJEU case law and, 55–9
 - clinical trials regulation and, 302–5
 - competition and equality in health systems and, 227–9
 - consumer rights in health care and, 73–5
 - cross-border movement of goods and services and, 101–5
 - EU health law and, 34–40, 63–9, 537–8
 - EU instruments, legislation and agreements and, 6–9

- ‘Europe 2020’ strategy and, 45–50
- food laws and, 404–8, 410–13
- free movement of goods and services and, 179–81, 194–8, 199–202
- health rights *versus* human rights and, 170–6
- intellectual property and, 108–12
- medical products and services and, 124–6
- objective public interest justifications and, 88–91
- patient and consumer protections and, 114–16
- patients’ rights and, 78–82, 179–81, 206–10
- Patient’s Rights Directive and, 85–8
- pharmacy services and products regulations and, 120–4
- population health and, 387–90
- private individual’s litigation and, 105–8
- Product Liability Directive and, 379–84
- restrictions on free movement and, 83–5, 179–81
- risk regulation and, 424–31
- service providers and posted workers and, 137–40
- social security entitlements coordination and, 199–202
- tobacco regulation and, 399–403
- ‘International Activities: A Strategic Approach’ (EFSA), 517–22
- International Conference on Harmonisation of Technical Requirements of Pharmaceuticals for Human Use (ICH)
- clinical trials guidelines and, 305–12
- cross-border movement of products and services and, 100–5
- global health law and, 437–43, 455
- paediatric pharmaceuticals and, 334–7
- pharmaceuticals law and, 324–7
- safety of medicines and, 504–8
- International Covenant on Economic, Social and Cultural Rights, 448–51
- International Encyclopaedia for Medical Law*, 15–17
- International Health Regulations (IHR)
- communicable diseases and, 508–11
- global health issues and, 448–51
- international law
- alcohol, food and tobacco regulations and, 437–43
- EU health law and, 445–7
- external health law and, 433–7
- health rights in, 156–60
- International Medical Malpractice Law* (Giesen), 15–17
- International Medical Products
- Anti-Counterfeiting Taskforce (IMPACT), 492–8
- International Monetary Fund (IMF), 437–43
- impact in EU health law of austerity programs, 52–3
- international organizations
- global health laws and, 437–43, 447–57
- patient’s rights concepts in, 184–9
- International Sanitary Conference (1851), 508–11
- International Sanitary Convention, 508–11
- International Sanitary Regulations, 508–11
- Internet
- opticians and ophthalmologists sales on, 264–5
- pharmacy regulations and drug sales on, 120–4
- in vitro* diagnostic devices, regulation of, 368–71
- in vitro* Medical Devices Regulation, proposal for, 371–8
- Iran, sale of human organs in, 473–7
- Ireland, Republic of
- constitutional protection of foetus in, 181n188
- ethical sensitivity issues and national courts of, 91–6
- industry relations with health professionals in, 285–8
- pricing challenges and generic promotion in, 278–81
- substitutive private health insurance in, 237–40, 243–6
- IRIS-H* case, 247–52
- Irish court system, abortion law challenges and, 55–9
- Italian Antitrust Authority Autorità Garante della Concorrenza e del Mercato, 229–35, 261–2, 278–81
- Italy
- competition law and freedom to trade in, 229–35
- medical device regulation in, 366–7
- origins of health laws in, 13–17
- ‘parapharmacy’ sector in, 252–9
- patients’ rights in, 185–9

- Jackson, Emily, 333–4, 337–41, 498–501
Jakab, Zsuzsanna, 512–17
Jarman, Holly, 451–4
judicial review
 of EU institutions, 55–9
 human rights constraints and, 170–6
 right to health care development and, 160–4
Juers Pharma Import–Export GmbH, 113–14
justice, global health law and, 433–7
- Kaltoft*, 414–18
Kamberaj case, 176–7
Karl, Beatrice, 222–5
Kennedy, Ian, 15–17
Keogh, Sir Bruce, 3–4
KerOptika case, 101–5
‘killing games’ ban, 179–81
Kilpatrick, Claire, 176–7
Klein, Rudolph, 211–13
‘knowledge production’ in health research, 503–4
Kohll case, 55–9, 75–83, 88–91, 119–20, 194–8, 247–52, 262–4
Konjac food additive, 404–8
Konstantinides case, 202–6
Krajewski, M., 451–4
Kurzer, Paulette, 417–18
- labelling regulations
 alcohol, 418–23
 EU food safety law and policy and, 523–6
 food labelling laws, 410–13
 for pharmaceuticals, 337–41
 tobacco, 526–30
 tobacco packaging, 394–6
laboratory practices
 CJEU case law on, 58n193
 patient mobility rights and reimbursement for, 78–82
 regulation of, 23–4
labour standards, service providers and posted workers and, 137–40
La Médecine et Le Droit (Nys), 15–17
Latvia, pricing challenges and generic promotion in, 278–81
Laufs, Adolf, 15–17
League of Nations Covenant, 508–11
Lear, Julia, 222–5
least developed countries
 essential medicines in, 483–5
 in-patent medicines and generics in, 486–92
 medical tourism and, 437–43
- Lee, R.G., 91–6
Legal Protection of Biotechnological Inventions Directive (98/44/EC), 40, 160–4, 170–6
 human tissue and cells and, 352–8
legal representative, Clinical Trials Directive guidelines concerning, 312–19
legal typologies, health system organization and, 219–21
Léger case, 363–5
legislative process in health law, 63–9
 human rights constraints on, 170–6
 social security entitlements coordination with patients’ rights and, 189–94
Lemmens, Trudo, 337–41
lex specialis rule
 blood and blood product safety and, 349–52
 food labelling regulations and, 410–13
liberal welfare models, competition and equality in health systems and, 227–9
licensing and qualification procedures
 counterfeit/falsified medicines and, 492–8
 health law and, 23–4
 health professionals regulation and, 142, 146–51
 intellectual property rights and, 486–92
 mainstreaming of health law into, 60–3
 pharmacy products and services regulations and, 120–4
 self-employed and employed health professionals, 132–7
lifestyle choices
 EU regulations and, 387–90
 public health regulations and, 423–4
Lindqvist case, 170–6
linguistic ability of health professionals, 146–51
Lisbon, Treaty of
 coherence in EU health law and, 40–53
 common commercial policy and, 492–8
 EU health legislation and, 65–6
 EU trade law and, 457–63
 global health and, 445–7
 human rights and, 156–60
 politics surrounding, 142–6
‘Lisbon Agenda’ for growth and development, EU health law and, 45–50
Lithuania, patients’ rights in, 185–9
litigation costs and procedures
 CJEU case law and, 55–9
 health law creation and, 265–8
Littoz-Monnet, Annabelle, 333–4

- lobbying activities
 - alcohol regulation and, 418–23
 - development of EU food laws and, 404–8
 - public health policies and, 423–4
 - tobacco regulation and, 392–4
- locus standi* of individuals, 170n111
- Lomé Convention, 463–9
- London College of Physicians, 13–17
- Longley, Diane, 220n43
- Lucien Ortscheit GmbH, 113–14
- Luisi and Carbone* decision, 60–3
- Lundbeck company, 281–5
- Maastricht, Treaty of
 - coherence in EU health law and, 40–53
 - EU communicable diseases law and, 512–17
- Macfarlan Smith company, 270–8
- McKee, Martin, 129–30, 391–2
- MacQuen* case, 264–5
- Madden, Deidre, 15–17
- mail order pharmaceuticals, pharmacy
 - products and services regulations and, 120–4
- mainstreaming of health law, EU treaties and instruments and, 60–3, 535–6
- Major, John, 65
- Major Medical Equipment* case, objective
 - public interest justifications and, 88–91
- malpractice law, professional liability and, 22–3
- Maltese National blood Transfusion Centre, 261–2
- managed competition, administrative/legal
 - typologies for health systems and, 219–21
- market authorization
 - centralized and decentralized procedures for, 327–34
 - CJEU case law on, 55–9, 538–40
 - dental clinics and, 262–4
 - food laws and, 404–8
 - generics, 327–34, 341–7
 - globalization of health research and, 504–8
 - harmonization of pharmaceutical laws and, 324–7
 - human rights constraints on, 170–6
 - of medical devices and products, 270–8, 368–78
 - paediatric pharmaceuticals, 334–7
 - patient and consumer protection rules and, 114–16
 - for pharmaceuticals, 270–8, 327–34
 - pricing challenges and generic promotion in, 278–81
 - social security entitlements coordination and, 199–202
 - tobacco products, 396–403
- ‘market pathway’ model
 - intellectual property and, 341–7
 - pharmaceutical products regulation, 108–12
- market preferences
 - clinical trials regulation and, 302–5
 - competition and equality in health systems and, 227–9, 288–91
 - consumer rights in health care and, 73–5
 - continuum of health system typologies and, 222–5
- data protection and privacy and, 170–6
- generic products entry and, 281–5
- global health law and, 433–7
- health professionals regulation and, 142–54
- hospital services regulation and, 247–52
- laboratories regulations and, 259–61
- organ donation and transplantation and, 473–7
- paediatric pharmaceuticals and, 334–7
- pharmaceuticals and medical devices and products, 270–8
- pharmacies regulations and, 252–9
- restrictions on free movement and, 179–81
- risk regulation and, 225–6, 295–301, 424–31
- trade agreements and, 451–4
- Marmor, Theodore, 211–13
- Mas, Jean-Claude, 3
- Masterson, Alan, 91–6
- Masterson, Louise, 91–6
- Médecins Sans Frontières, 498–501
- medical aid organizations, competition law and freedom to trade decisions and, 229–35
- medical devices and products industry. *See also* medicinal products
 - applicable law for cross-border movement of, 100–5
 - assessment of challenges to, 288–91
 - assessment of EU approach to, 384–6
 - compensation for harm and, 379–84
 - competition, solidarity and equality and, 269–70
 - current trends in, 548–50
 - definition of, 368–71
 - EU health law and, 34–40, 53–5, 124–6, 322–4, 366–71, 378, 548–50

- medical devices and products industry (*cont.*)
 EU trade law and, 366–7, 457–63
 free movement of goods and services and, 98–100
 generic competition promotion, 278–81
 global market and, 437–43
 health professionals' relations with, 285–8
 history of regulation concerning, 366–7
 industry challenges to regulation of, 108–24, 281–5
 internal market strategies and regulation of, 34–40
 knowledge production and, 504–8
 market authorization and preferences in, 270–8
 objective public interest justifications and, 88–91
 patient and consumer protection rules and, 112–18
 price and profit regulations and
 reimbursement restrictions, 119–20
 private individuals' litigation against, 105–8
 reform of regulations concerning, 371–8
 risk regulation and, 424–31
 tortious liability for defective products and, 63–9
 Medical Devices Directive (93/42/EEC), 270–8
 Medical Devices Regulation, proposal for, 371–8
 medical education
 entry into health professions and, 142–6
 global health laws and, 437–43
 medicalization of health care, by
 pharmaceutical industry, 337–41
Medical Law (Westerhäll), 15–17
Medical Law in Belgium, 15–17
Medical Law in Germany, 15–17
Medical Law in Ireland (Madden), 15–17
 medical law terminology, health law and, 10, 15–17
Medical Law: Text and Materials, 15–17
 'medical purpose' principle, medical device
 and products regulation and, 371–8
 medical tourism
 global market for health products and, 5–6, 437–43
 organ donation and transplantation and, 472–83
 Medicinal Orders (Germany), 13–17
 medicinal products. *See also* blood and blood
 products
 blood or plasma-related products, 349–52
 Clinical Trials Directive definition and
 regulation of, 305–12
 EU definition of, 324–7
 incentives for medicine development in
 global South, 498–501
 orphan drugs and, 334–7
Medicine, Ethics and the Law (Madden), 15–17
Medicine and Law journal, 15–17
 Medicines Act (Germany), 379–84
 'Medicrime' Convention (Council of Europe),
 492–8
Medipac case, 34–40
 Member States of EU
 administrative/legal typologies of health
 systems in, 219–21
 alcohol regulation and, 418–23
 anti-competitive strategies and, 278–81
 assessment of health law in, 544–6
 blood and human tissue centres in, 261–2
 Blood Safety Directive and, 261–2, 349–52
 CJEU case law supremacy and, 55–9
 clinical trial regulations, 302–12
 colonialism and, 463–9
 compensation for harm from
 pharmaceuticals and medical products
 and, 379–84
 competition law in, 229–35, 265–8, 288–91
 continuum of health system typologies in,
 222–5
 coordination of free movement law with
 social security entitlements in, 199–202
 Council of Europe and, 65
 dental clinics and, 262–4
 development disparities in, 12n10
 differences in health care regulation by, 4–5
 equality in health systems in, 215–16
 EU communicable diseases law and, 53–5,
 512–17
 EU development strategies and, 463–9
 EU trade law and, 457–63
 food laws and, 404–8
 free movement law and, 179–81, 229–35,
 243–6, 265–8, 288–91
 funding of health care services in, 220–1
 generic competition and pricing challenges
 in, 278–81
 global health law and, 443–4
 harmonization of pharmaceutical laws in,
 324–7
 health professionals regulations in, 127–37

- health rights and constitutions of, 160–4
- health systems comparisons in, 213–18
- health technology regulations and, 348–9
- hospital regulation in, 247–52
- human rights protections and, 156–60
- Human Tissue and Cells Directive
2004/23/EC, 349–58
- industry challenges to pricing restrictions
by, 281–5
- International Health Regulations and,
508–11
- laboratories regulations and, 259–61
- market authorization of pharmaceuticals in,
327–34
- ‘market pathway’ model for pharmaceuticals
regulation and, 341–7
- medical devices and products regulation
and, 270–8, 371–8
- medicinal products development and,
108–12, 498–501
- national ethical sensitivity issues and, 91–6
- national healthcare legislation, table of
countries, lxiii
- opticians and ophthalmologists and, 264–5
- organ transplantation in, 358–60, 473–7
- origins of health laws in, 13–17
- patient’s rights legislation in, 184–9
- pharmaceutical packaging, labelling and
advertising and language differences in,
337–41
- pharmaceuticals regulations in, 108–12,
270–8
- pharmacies regulation and, 252–9
- population health and autonomy of, 387–90
- privatization of health services in, 451–4
- professional practice guidelines in, 146–51
- reform pressures and efficiency of health
systems in, 216–18
- right to health care obligations of, 176–7,
213–14
- social security entitlements coordination in,
189–94, 199–202
- social *versus* private insurance in, 235–43
- solidarity principle in health systems of,
214–15
- systemic focus on healthcare in, 211–13
- tobacco regulations in, 390–403
- treaty ratification by, 63–9
- working time for health professionals and,
140–2
- mental capacity
 - Clinical Trials Directive guidelines on,
312–19
 - health law and, 26–7
- mental health
 - as human right, 160–4
 - scope of EU health law on, 42–3
 - social care and, 12n11
- merger regulations
 - competition and freedom to trade in health
systems and, 229–35
 - health professionals relations with industry
and, 285–8
 - hospitals and, 247–52
- Merkur, Sherry, 129–30
- Mesopotamian Code of Hammurabi, 13–17
- Methicillin-resistant *Staphylococcus aureus*
(MRSA), regulation of health care and,
23–4
- ‘me-too’ pharmaceuticals, harmonization of
EU laws and, 324–7
- migrant patients
 - EU health legislation and, 64
 - privatization of health services and, 451–4
 - social security entitlements coordination
with rights of, 189–94
- Millennium Development Goals, 463–9
 - essential medicines and, 483–5
 - global health law and, 448–51
- Miola, José, 17–19
- mixed agreements, EU trade law and,
457–63
- mobile workers. *See also* posted workers
 - access to health care for, 60–3
 - entry into health professions and, 142–6
 - health professionals as, 127–37, 154–5
 - social security entitlements coordination
with rights of, 189–94
- modified liberal health systems, 222–5
- monitoring procedures
 - in Clinical Trials Directive, 305–12
 - risk in clinical trials, 319–20
- monopolies rules
 - competition and freedom to trade in health
systems and, 229–35
 - in competition and free movement law,
235–43
- Montgomery, Jonathan, 11–13
- Moreno, Luis, 227–9
- Morgan, Derek, 10, 91–6
- Mossialos, Elias, 222–5, 241–2, 243–6
- Müller-Fauré case, 83–5, 199–202

- Multiannual Framework, Fundamental Rights Agency, 166–9
- multi-centered clinical trials, Clinical Trials Directive and, 305–12
- multilateral framework treaties
 - EU development policies and, 463–9
 - intellectual property rights and, 496–8
- Murphy, Thérèse., 295–301
- mutual recognition principle
 - alcohol regulation and, 418–23
 - entry into health professions and, 142–6
 - internal market strategies for EU health law and, 34–40
 - pharmaceuticals and medical device purchases and, 270–8
 - private individual’s litigation and, 105–8
 - self-employed and employed health professionals and, 132–7
- nanomedicine, EU regulation of, 322–4
- Napp* case, 278–81
- National Board of the French Dental Surgeons Associations, 285–8
- national constitutional law
 - ethical sensitivity issues and, 91–6
 - patient’s rights concepts in, 185–9
- national court systems
 - CJEU case law and, 55–9
 - ethical sensitivity issues and, 91–6
 - free movement of goods and services and, 98–100
 - health rights as human rights and, 172–6
 - health rights law and, 160–4
 - right to health care and, 176–7
- national development initiatives, EU
 - development strategies and, 463–9
- national ethical sensitivity
 - human materials regulations and, 361–5
 - patient rights and, 91–6
- National Health Service (NHS) (United Kingdom)
 - CJEU case law and, 55–9
 - medical device regulation in, 366–7
 - origins of health law and introduction of, 13–17
- national health systems
 - administrative/legal typologies in, 219–21
 - anti-competitive strategies and, 278–81
 - assessment of, 544–6
 - CJEU case law supremacy and, 55–9, 75–6
 - Clinical Trials Directive and Regulation and, 312–19
 - continuum of typologies for, 222–5
 - cross-border medical treatment and, 83–5, 101–5
 - dental clinics and, 262–4
 - entry into health professions and, 142–6
 - equality in, 215–16
 - EU health law and, 4–5, 13–17, 30–3, 68–9, 540–4
 - EU trade law and, 457–63
 - freedom to trade across borders and, 227–9
 - free movement of goods and services and, 101–5, 194–8, 199–202
 - funding typologies for, 220–1
 - generic competition and pricing challenges in, 278–81
 - generic products entry into, 281–5
 - health insurance organization in, 243–6
 - health professionals regulation in, 127–37, 142–6
 - health technology regulations and, 348–9
 - human materials regulations and, 361–5
 - industry challenges to pricing restrictions by, 281–5
 - industry relations with health professionals and, 285–8
 - intellectual property rules and, 108–12
 - internal health law and, 211–13
 - laboratories regulations and, 259–61
 - national ethical sensitivity issues and, 91–6
 - opticians and ophthalmologists and, 105–8, 264–5
 - patient and consumer protection rules and, 112–18
 - patients’ rights and, 76–83, 85–8, 194n77, 199–202
 - pharmaceuticals and medical devices and equipment and, 269–70
 - population health and autonomy of, 387–90
 - price and profit regulations and reimbursement restrictions, 119–20
 - private individuals’ litigation against, 105–8
 - reform pressures and efficiency in, 216–18
 - right to health care in, 213–14
 - risk regulation in, 225–6
 - service providers and posted workers, 137–40
 - social security entitlements coordination with, 189–94, 199–202
 - solidarity principle in, 214–15
 - table of countries with, lxiii

- ‘neglected tropical diseases’, medicine
 - development and, 498–501
- negligence, professional liability in health law and, 22–3
- neoliberal health systems, 222–5
 - clinical trials regulation and, 302n57
 - competition and free movement law and, 235–43
 - EU health law and influence of, 288–91
 - planned economy health systems *versus*, 227–9
- ‘neo-prohibitionist’ approach, tobacco regulation and, 399–403
- Netherlands
 - competition laws and hospitals in, 247–52
 - entry into health professions in, 142–6
 - health insurance framework in, 240
 - industry relations with health professionals in, 285–8
 - patients’ rights in, 185–9
 - pharmaceutical price and profit restrictions and, 119–20
 - pharmacies’ regulations in, 257–9
 - pharmacy products and services regulations in, 120–4
- Netherlands Competition Authority, 247–52
- Netherlands v. European Parliament and Council (Biotechnology Directive)*, 160–4, 361–5
- neural crest cell development
 - human rights constraints and, 170–6
 - regulation of, 352–8
- Nevirapine, time-limited donations of, 490–1
- ‘new generation’ trade agreements, intellectual property rights and, 486–92
- Nice, Treaty of, EU trade law and, 457–63
- ‘no cream-skimming’ argument, competition law and freedom to trade decisions and, 229–35
- non-commodification of health care
 - health professionals and, 127–32
 - human materials regulations and, 182
 - medical products and services and, 124–6
 - non-commodification of human body and, 361–5
 - organ donation and transplantation and, 478–83
- non-discrimination principles
 - EU Fundamental Rights Agency, 166–9
 - obesity laws and, 414–18
 - pharmaceuticals and medical device purchases and, 270–8
 - right to health care and, 176–7
- non-hospital settings
 - health law regulation of, 23–4
 - objective public interest justifications and, 88–91
 - patients’ rights in, 206–10
- non-life insurance
 - competition and free movement law and, 235–43
 - cross-border movement of health goods and services and, 101–5
 - free movement law and, 241–2
- Nordic Health Law in a European Context* (Rynning and Hartlev), 15–17
- normative principles
 - soft laws in EU health legislation and, 59–60
 - tobacco law and policy and, 526–30
- ‘notified bodies’ oversight, internal market strategies for EU health law and, 34–40
- Novartis company, 346–7
- ‘novel tobacco products’, regulation of, 396–9
- ‘nudging strategy’
 - alcohol regulation and, 418–23
 - tobacco regulation and, 399–403
- Nuffield Council on Bioethics (UK), 25–6, 387–90
- Nuremberg Trials
 - evolution of clinical trials regulation and, 302–5
 - health law and, 26–7
- nursing profession, EU regulations
 - concerning, 136–7
- nutrition labelling regulations, 404–8, 410–13
 - alcohol, 418–23
- Nys, Herman, 15–17
- obesity concerns, food laws and, 404–8, 414–18
- objective public interest justifications. *See also* public interest principle
 - consumer rights framework and, 88–91
 - food laws and, 404–8
 - pharmaceuticals and medical device purchases and, 270–8
 - restrictions on free movement and, 179–81
 - self-employed and employed health professionals and, 132–7
- Offe, Clause, 227–9

- L’Office International d’Hygiène Publique* (OIHP), 508–11
- Official Food and Feeds Control Regulation 882/2004/EC, 517–22
- Olivieri v. Commission* case, 170n111
- Omega Spielhallen, 179–81
- ‘on call’ systems for health professionals, working time regulations and, 151–3
- open markets, cross-border movement of goods and services and, 101–5
- Open Method of Coordination (OMC)
 - EU health law and, 45–50
 - European Commission agreement on, 64
 - EU working groups and, 67–8
 - Member States health care systems and, 75n12
 - welfare paradigm and, 227–9
- opticians and ophthalmologists, free movement of goods and services regulations and, 105–8, 264–5
- opt-outs
 - organ transplantation consent, 358–60
 - working time for health professionals and, 140–2, 151–3
- Ordre national des pharmaciens* (France), 259–61
- organ donation and transplantation
 - competition law and freedom to trade concerning, 229–35
 - EU regulation of, 358–60, 478–83, 540–4
 - future challenges in, 546–8
 - global market in, 472–83
 - health rights concerning, 160–4
 - voluntary/unpaid donations regulations, 361–5
- Organisation for Economic Cooperation and Development (OECD)
 - counterfeit/falsified medicines and, 492–8
 - global health law and, 457
 - health indicators from, 67–8
- Organ Safety Directive (2010/53/EU)
 - consent focus in, 361–5
 - establishment of, 358–60
- Organ Transplant Directive (2010/53/EU), 478–83
- O’Rourke, Raymond, 408–10
- orphan drugs
 - internal market strategies for EU health law and, 34–40
 - in national health systems, 270n1
 - regulation of, 334–7
- Ortscheit* case, 113–16
- Ost, Suzanne, 13–17
- over-the-counter pharmaceuticals
 - advertising regulations for, 337–41
 - cross-border movement of goods and services and, 101–5
 - pharmacies regulations and, 252–9
 - pharmacy products and services regulations and, 120–4
 - private individuals’ litigation involving, 105–8
- Oviedo Convention, 361–5, 455–7
- ownership rules, pharmacies regulations and, 252–9
- Oxfam, 496–8
- packaging regulations
 - blood and blood products, 349–52
 - counterfeit/falsified medicines and, 492–8
 - for pharmaceuticals, 337–41
 - tobacco, 394–6
- Paediatric Committee (EU), 334–7
- ‘paediatric investigation plan’, 334–7
- Palier, Bruno, 227–9
- ‘para-law’ functions of soft law, 59–60
- parallel importing
 - delayed entry of generic products and, 281–5
 - industry challenges to restrictions on, 282n60
 - ‘market pathway’ model for pharmaceuticals regulation and, 341–7
 - medical devices and products and, 270–8
 - pharmacy products and services restrictions and, 108–12, 119–24, 270–8
 - ‘parapharmacy’ sector, regulation of, 252–9
- Parkinson’s disease, 352–8
 - human rights constraints on innovations for, 170–6
- patent law. *See also* in-patent pharmaceuticals
 - expirations and, 285–8
 - global health law and, 433–43
 - global patent laws, 483–5
 - harmonization of pharmaceutical laws and, 324–7
 - in-patent medicines and generics and, 486–92
 - ‘market pathway’ model for pharmaceuticals regulation and, 341–7
 - risk regulation and, 424–31
 - ‘supplementary patent certificate’ and, 341–7

- paternalism in health care practices
 - patient mobility rights and, 78–82
 - risk regulation and, 424–31
- patient choice and mobility. *See also*
 - cross-border health services
 - CJEU case law concerning, 55–9, 76–83, 96–7
 - in continuum of health system typologies, 222–5
 - in EU health legislation, 53–5, 75–6, 538–40
 - free movement of goods and services and, 98–100
 - global perspectives in health and, 437–43
 - hospital regulations and, 247–52
 - individual perspectives in health law and, 71–2
 - national ethical sensitivity issues and, 91–6
 - objective public interest justifications and, 88–91
 - organ donation and transplantation and, 473–7
 - social security entitlements coordination with, 76–83, 184–5, 189–94
- ‘patient cliff’, 285–8
- patient-physician relationships
 - health law and, 20
 - health professional regulations and, 154–5
 - internal EU health law and, 71–2
 - origins of health law and, 15–17
 - private individual’s litigation and, 105–8
 - professional practice guidelines and, 146–51
- Patients’ Rights in Cross-Border Health Care Directive (2011/24/EU), 50–3, 75–6, 82
 - access to healthcare and EU citizenship in, 202–6
 - assessment of, 206–10
 - free movement of goods and services and, 194–8, 199–202
 - future potential of, 546–8
 - health rights as human rights and, 156–60, 170–6, 184–5
 - hospital regulations and, 247–52
 - internal market law and, 85–8
 - international and comparative contexts for, 185–9
 - objective public interest justifications and, 88–91
 - pharmacy products and services regulations and, 120–4
 - social security coordination with, 76–83, 184–5, 189–94, 199–202
- Pavlov case*, 229–35
- ‘pay for delay’ arrangements, generic products entry and, 281–5
- Peerbooms case*, 164–6, 199–202
- peer regulation, administrative/legal typologies for health systems and, 219–21
- Pfizer group, pricing challenges and generic promotion and, 278–81
- pharmaceutical industry. *See also*
 - counterfeit/falsified medicines; medical devices and products; over-the-counter pharmaceuticals; prescription-only pharmaceuticals
 - advertisement of pharmaceuticals in, 113–14
 - challenges to pricing regulations by, 281–5
 - CJEU case law on pricing transparency and, 55–9
 - Clinical Trials Directive scope, obligations, and responsibilities and, 305–12
 - clinical trials regulation and, 302–5
 - compensation for harm from products of, 379–84
 - cross-border movement of goods and services and, 101–5
 - essential medicines and, 483–5
 - EU regulation of, 45–50, 53–5, 269–70, 288–91, 324–47, 384–6
 - EU trade law and, 457–63
 - global market and, 437–43
 - health professionals’ relations with, 285–8
 - in-patent medicines protections and, 486–92
 - intellectual property rules and, 108–12, 341–7
 - internal market legislation and, 39–40, 63–9
 - knowledge production and, 504–8
 - litigation brought by firms in, 108–24
 - market authorization regulations and, 270–8, 327–34
 - ‘market pathway’ concept and, 341–7
 - Member States preferences concerning, 65
 - packaging, labelling and advertising regulations, 337–41
 - paediatric pharmaceuticals regulation and, 334–7
 - patient and consumer protection rules and, 112–18

- pharmaceutical industry (*cont.*)
 - price and profit regulations and reimbursement restrictions, 119–20
 - pricing challenges and generic competition promotion, 278–81
 - private capitalization of, 483–5
 - risk regulation and, 295–301, 424–31
- pharmacies
 - competition, solidarity and equality and regulation of, 252–9
 - regulation of, 23–4
 - services and product provision, regulations involving, 120–4
 - trading rules for, 257–9
- ‘pharmacovigilance’
 - EU focus on, 53–5
 - harmonization of pharmaceutical laws and, 324–7
- Philip Morris International, 392–4
- physicians. *See also* health care services; health professionals
 - in early EU health law, 30–3
 - entry into profession for, 142–6
 - industry relations with, 285–8
 - origins of health law and role of, 15–17
 - professional liability in health law and, 22–3
- Pierik (No. 1) case*, 189–94
- Pierson, Paul, 216–18
- plain packaging laws, tobacco and, 394–6
- planned economy health systems, 222–5
 - neoliberalism *versus*, 227–9
- ‘Platform on Diet, Nutrition, and Physical Activity’, 67–8, 417–18
- pluralistic health systems, 219–21
- Poland, industry relations with health professionals in, 285–8
- Polanyi, K., 227–9
- policy-making structure
 - alcohol regulation and, 418–23
 - CJEU case law and, 55–9
 - human rights constraints on, 170–6
 - mainstreaming of health law into, 60–3
 - trade agreements and, 451–4
- politics
 - alcohol regulation and, 418–23
 - blood and blood product safety and, 349–52
 - Clinical Trials Directive and Regulation and, 312–19
 - EU communicable diseases law and, 512–17
 - health law and, 27–8
 - legislative and judicial procedures in EU health law and, 68–9
 - market authorization of pharmaceuticals and, 327–34
 - public health policies and, 387–90
 - risk regulation and, 295–301, 424–31
- Poly Implant Prothèse case, 292–5, 548–50
 - fraud and abuse and, 3–9
 - internal market strategies for EU health law and, 36
- population health
 - essential medicines and, 483–5
 - EU policies and, 387–90
 - status of health professionals and, 127–32
- Portugal, restrictions on medical treatment in, 83–5
- posted workers
 - EU health regulations concerning, 137–40, 153–4
 - social security entitlements coordination with patients’ rights and, 189–94
- ‘Posted Workers’ Directive 96/71/EC, 137–40
- ‘post-law’ functions of soft law, 59–60
- Poteliakhoff, Emmi, 216–18
- poverty. *See also* economics and health
 - EU development initiatives and, 463–9
 - EU health law and, 30–3, 53–5, 67–8
 - in global health context, 437–43, 448–51, 472
 - health status and, 11–13, 387–90
 - OECD data on, 457
- organ donation and transplantation and, 473–7
- right to health and, 156–60, 176–7
- precautionary principle
 - Agreement on the Application of Sanitary and Phytosanitary Measures and, 451–4
 - blood and blood product safety and, 349–52
 - clinical trial regulation and, 302–5
 - in Clinical Trials Directive, 305–12
 - risk regulation and, 298–301
- predatory pricing, Member states’ challenges to, 278–81
- pre-implantation gender selection, ethical sensitivity issues and, 91–6
- ‘pre-law’ functions of soft law, 59–60
- preliminary reference procedure
 - CJEU case law and, 55–9
 - entry into health professions and, 142–6

- prescription-only pharmaceuticals
 - advertising restrictions for, 337–41
 - cross-border movement of goods and services and, 101–5
 - pharmacies’ regulations and, 252–9
 - pharmacy products and services regulations and, 120–4
 - price and profit regulations and reimbursement restrictions, 119–20
- presumed consent. *See* consent
- preventive health practices
 - EU health legislation on, 53–5
 - scope of EU health law on, 42–3
- price and profit regulations
 - assessment of, 288–91
 - dental clinics and, 262–4
 - essential medicines and, 486–92
 - in EU health laws, 119–20
 - generic competition and, 278–81
 - industry challenges to, 281–5
 - laboratories regulations and, 259–61
 - ‘market pathway’ model for pharmaceuticals regulation and, 341–7
 - orphan drugs and, 270n1
 - pharmaceuticals and medical devices and products and, 270–8
 - pharmacies and, 252–9
- primary law
 - EU instruments and legislation, xxxviii–xli
 - free movement of goods and services and patient mobility and, 194–8
 - origins of health law and, 13–17
- prior authorization requirements
 - objective public interest justifications and, 88–91
 - Patient’s Rights Directive and, 85–8
 - restrictions on cross-border medical treatment and, 83–5
- priority review vouchers, medicinal product development and, 498–501
- privacy issues
 - Data Protection Directive and, 101–5
 - in EU health legislation, 20–2, 26–7, 53–5
 - human right to privacy, 160–4, 172–6
 - patient’s rights and, 185–9
 - suspension of health professionals and, 146–51
- private health insurance and services
 - blood and human tissue centres and, 261–2
 - competition and free movement laws and, 235–46
 - continuum of health system typologies and, 222–5
 - cross-border movement of health goods and services and, 101–5
 - global pharmaceutical industry and, 483–5
 - health professionals relations with, 285–8
 - hospitals, 247–52
 - medical tourism and, 437–43
 - patients’ rights concerning, 194–8
 - self-employed and employed health professionals, 132–7
- private individuals, litigation by, 105–8
 - pharmaceutical price and profit restrictions and, 119–20
- procedural issues
 - clinical trials regulation and, 302–5
 - compensation for harm from pharmaceuticals and medical devices and, 379–84
 - patients’ rights and, 206–10
- Product Liability Directive (85/374/EEC)
 - compensation for harm from pharmaceuticals and medical devices and, 379–84
 - cross-border movement of products and services and, 100–5
- product liability legislation, internal market strategies for EU health law and, 34–40
- professional development and accreditation
 - Blood Safety Directive and, 349–52
 - global health laws, 437–43
 - for health professionals, 146–51
 - industry influence on, 285–8
 - working time regulations and, 151–3
- professional health care providers. *See* health professionals
- Professional Qualifications Directive (2005/36/EC), 136–40, 146–51
- prophylactic treatment, health law and, 26–7
- proportionality test
 - competition law and freedom to trade decisions and, 229–35
 - complementary private insurance and, 237–40, 243–6
 - food laws and, 404–8
 - objective public interest justifications and, 88–91
 - patient and consumer protection rules and, 113–14
 - pharmaceuticals and medical device purchases and, 270–8

proprietary medicines, market authorization for, 327–34	medical devices and products, 368–71
public health	patient mobility rights and, 198
alcohol regulation and, 118, 387–90, 418–23	pharmacies regulation and, 252–9
competition law and freedom to trade regulations and, 229–35	professional practice guidelines and, 146–51
EU communicable diseases law and, 512–17	regulation of health care and, 23–4
EU development policies and, 463–9	
in EU health law, 25–6, 30–3	Red Cross/Red Crescent, 478–83
EU trade agreements and, 457–63	reform pressures and efficiency, in EU health systems, 216–18
Executive Agency for Health and Consumers programmes for, 67–8	refugees, social security entitlements coordination with patients’ rights and, 189–94
food regulation and, 387–90, 403–18	refusal of treatment, patient’s rights and, 185–9
global health law and, 433–43	Regional Harmonisation Initiatives (RHIs), 455
industry influence on professionals in, 285–8	Regulation 141/2000/EC on orphan drugs, 334–7
in-patent medicines and generics and, 486–92	Regulation 178/2002/EC on food safety, 517–22
International Health Regulations and, 508–11	Regulation 260/2009/EU on import rules, 457–63
international organizations for, 448–51	Regulation 282/2014/EU for public health, 512–17
national <i>versus</i> EU decision-making on, 423–4	Regulation 432/2012/EU on food health claims, 410–13
pharmacies regulations and, 252–9	Regulation 608/2013/EU on customs authorization, 492–8
pharmacy products and services regulations and, 120–4	Regulation 883/2004/EC on social security systems coordination
politics and, 27–8	free movement of goods and services and, 194–8, 199–202
self-employed and employed health professionals and, 132–7	patient mobility and sickness insurance in, 78–82, 189–94
tobacco regulations and, 387–90	Patient’s Rights Directive and, 83–8, 96, 127–32
‘Public Health: The Ethical Issues’, 25–6	recent ‘restriction’ interpretations and, 83–5
public interest principle. <i>See also</i> objective public interest justifications	Regulation 953/2003/EC on trade diversion of medicines, 486–92
clinical trials regulation and, 302–5	Regulation 1169/2011/EU on food information to consumers, 410–13, 418–23
free movement of goods and services and, 194–8	Regulation 1291/2013/EU on Framework Programme for research, 504–8
self-employed and employed health professionals and, 132–7	Regulation 1383/2003/EC on intellectual property rights, 492–8
public-private partnerships, medicine development and, 498–501	Regulation 1408/71/EEC on cross-border access to health care
public procurement legislation	free movement of goods and services and, 199–202
cross-border movement of health goods and services and, 101–5	patients’ rights and, 78–82, 189–94, 206–10
medical devices and equipment and, 270–8	restrictions on medical treatment in, 83–5
private health insurance and, 237–40	
service providers and posted workers and, 137–40	
quality assurance and control	
Blood Safety Directive and, 349–52	

- Regulation 1901/2006/EC on paediatric medicinal products, 334–7
- Regulation 1924/2006/EC on nutrition and health claims, 410–13
- regulation of health care
 - consumer rights and, 73–5
 - in early EU health law, 30–3
 - health laws and, 23–4
 - internal market strategies in EU for, 34–40
- reimbursement for treatment
 - EU restrictions on, 119–20
 - patient mobility rights and, 78–82
 - Patient’s Rights Directive and, 85–8
 - recent ‘restriction’ interpretations concerning, 83–5
 - social security/free movement coordination and, 199–202
 - solidarity in EU health systems for, 214–15
- relational contracting, competition and free movement law and, 235–43
- relevance criteria in health research, Clinical Trials Directive and Regulation and, 312–19
- religion
 - health law and, 17–19
 - health rights and, 170–6
- reporting obligations
 - in Clinical Trials Directive, 305–12
 - suspension of health professionals and, 146–51
- reproductive rights. *See also* contraception services
 - health law and, 20–2
 - indirect effect of human rights on, 182
 - judicial protection of, 160–4
 - national ethical sensitivity issues and, 91–6
 - restrictions on free movement and, 179–81
- Research Executive Agency, 67–8
- resource allocation, risk regulation and, 424–31
- Returns Directive (2008/115/EC), right to health care for third-country nationals in, 176–7
- right to health care
 - essential medicines and, 483–5
 - EU Fundamental Rights Agency, 166–9
 - in EU health law, 20–2, 53–5, 160–9, 170–6, 182–3, 213–14, 540–4
 - global health law and, 433–7
 - human rights and, 4, 156–60, 169–82
 - indirect effects of, 182
 - international organizations and, 448–51
 - judicial development of principles for, 160–4
 - non-discrimination/equality and, 176–7
 - pharmaceutical advertising and, 337–41
 - as public good, 483–5
 - public health and, 25–6
 - restrictions on free movement and, 179–81
 - treaty amendments and, 164–6
- Rindal* case, 83–5, 199–202
- ‘risk equalization scheme’, private health insurance and, 237–40
- risk regulation
 - assessment of EU approach to, 384–6, 544–6
 - in Clinical Trials Directive, 312–19
 - clinical trials policies and, 302–5
 - compensation for harm from pharmaceuticals and medical devices and, 379–84
 - continuum of health system typologies and, 225–6
 - cross-border movement of goods and services and, 101–5
 - EU food safety law and policy and, 404–8, 517–22
 - EU health law and, 6–9, 44–5, 295–301, 424–31, 540–4
 - food regulation and, 408–10, 423–4
 - globalization of health research and, 504–8
 - health technology and, 348–9
 - human materials ethics and, 360–1
 - legal challenges in, 292–5
 - market authorization of pharmaceuticals and, 327–34
 - ‘market pathway’ model for pharmaceuticals and, 341–7
 - medical device and products regulation and, 371–8
 - monitoring and transparency of risk, 319–20
 - patient mobility rights and, 198
 - pharmaceutical packaging, labelling and advertising and, 337–41
 - population health and, 387–90
 - questions and answers on, 556–8
 - systemic focus on healthcare and, 211–13
 - tobacco regulation and, 423–4
- Road Safety Action programme, 418–23
- Roma community, human rights protections for, 166–9
- Rosengren* case, 116–17
- Rottman* case, 202–6
- Roussel*, 119–20

- Royal Pharmaceutical Society (UK), Code of Ethics, 120–4
- Ruger, Jennifer Prah, 433–7
- Ruiz Zambrano case, 202–6
- rule-making procedures, development of EU health law and, 66–7
- rules-based classification, medical device and products regulation and, 371–8
- R. v. Human Fertilisation and Embryology Authority ex parte Blood*, 94–6, 160–4
- R. v. Royal Pharmaceutical Society Society of Great Britain*, 120–4
- R. v. Secretary of State for Health, ex parte British American Tobacco and Imperial Tobacco Ltd*, 526–30
- safety issues
 - clinical trials regulation and, 302–5
 - in EU legislation, 53–5
 - food regulation and, 408–10
 - health professionals working conditions and, 140–2
 - ‘market pathway’ model for pharmaceuticals and, 341–7
 - medical devices and products, 368–78
 - organ donation and transplantation and, 473–7, 480–1
 - patient mobility rights and, 198
 - pharmaceuticals and medical device regulations and, 270–8
 - product liability and, 379–84
 - regulation of health care and, 23–4
 - working time regulation for health professionals and, 140–2, 151–3
- sanctity of life principle, health law and, 17–19
- Sandel, Michael, 433–7
- Sanitas company, 285–8
- Santéclair company, 285–8
- Sauer, Fernand, 512–17
- Sauter, Wolf, 237–40, 243–6, 265–8, 281–5
- Scharpf, Fritz, 227–9
- Schumacher* case, 105–8
- ‘Science Strategy for 2012–2016’ (EFSA), 517–22
- scientific analysis
 - clinical trials guidelines and, 317–19, 320–1
 - food safety and, 408–10
 - market authorization of pharmaceuticals and, 327–34
 - medical devices and products industry regulation and, 371–8
 - risk management and, 295–301
 - scope of EU health law, 19–28, 42–3, 53–5, 60–3, 265–8
 - Clinical Trials Directive, 305–12
 - for medical devices and products industry, 368–71
- Scotch Whisky Association, 418–23
- Scotland, alcohol regulation in, 418–23
- screening procedures, health law and, 26–7
- secondary law
 - EU instruments and legislation, xli–lxi
 - social security entitlements coordination with freedom of movement and, 189–94
- second generation trade agreements, 462n108, 463–9
- ‘sectoral approach’ to mutual recognition principle
 - entry into health professions and, 142–6
 - self-employed and employed health professionals and, 132–7
- self-employed workers
 - competition law and freedom to trade decisions and, 229–35
 - health professionals as, 132–7, 146–51
 - social security entitlements coordination with rights of, 189–94
- self-regulatory structures
 - administrative/legal typologies for, 219–21
 - health law and evolution of, 23–4
 - health professionals and, 127–32
 - for medical devices, 366–7
- ‘Semashko system’ of healthcare, 222–5
- Sen, Amartya, 433–7
- Services in the Internal Market Directive (2006/123/EC)
 - health services excluded in, 101–5, 137–40
 - patients’ rights and, 85–8, 185–9
- ‘services of general interest’, EU legislative focus on, 53–5
- sexual orientation, ethics and human rights in
 - human materials regulation and, 361–5
- Shipman, Dr. Harold, 23–4
- sickness insurance
 - funding typologies for, 220–1
 - patient mobility rights and, 78–82
 - pharmaceutical price and profit restrictions and, 119–20

- restrictions on medical treatment and, 83–5
- social security entitlements coordination
 - with patients’ rights and, 189–94
 - as substitutive insurance, 237–40
- Single European Act, mainstreaming of EU health law and, 60–3
- single market model
 - cross-border movement of goods and services and, 101–5
 - health professionals and, 127–32
 - medical devices and products industry regulation and, 371–8
 - pharmaceutical products pricing and, 108–12
- Slovenia
 - free movement law and complementary insurance in, 241–2
 - patients’ rights in, 185–9
- smokeless tobacco, coherence in EU health law concerning, 45–50
- smoking, EU approaches to, 387–90. *See also* tobacco regulation
- social citizenship
 - consumer rights in health care and, 73–5
 - health rights as human rights and, 159–60
- social insurance healthcare model
 - administrative/legal typologies for, 219–21
 - competition law and freedom to trade decisions and, 235–43
 - continuum of health system typologies and, 222–5
 - free movement of goods and services and, 105–8
 - funding typology for, 220–1
 - intellectual property rules and, 108–12
 - patient mobility rights and, 76–83
- Social Protection Committee, 67–8
 - Open Method of Coordination and, 67–8
- social rights
 - CJEU rulings and, 265–8
 - EU health legislation and, 53–5
 - ‘Europe 2020’ strategy and, 45–50
 - health rights and, 160–4
 - internal markets and, 44–5
 - patient’s rights and, 185–9
 - right to health care and, 176–7, 206–10
- social security entitlements
 - EU citizenship and access to healthcare and, 202–6
 - free movement of services coordination with, 78–82, 199–202
 - objective public interest justifications and, 88–91
 - patients’ rights coordination with, 76–83, 184–5, 189–94
 - private health insurance and, 241–2
- soft law measures
 - alcohol regulation and, 418–23
 - competition law and freedom to trade decisions, 229–35
 - EU food safety law and policy and, 517–22
 - EU health law and, 59–60, 68–9, 538–40
 - EU regulatory bodies and, 66–7
 - food regulation and, 417–18
 - hard law interactions with, 68–9
 - health professionals and, 127–32
 - internal market strategies for EU health law and, 34–40
 - international law and, 445–7
 - medicinal products development and, 498–501
- solidarity principle
 - consumer rights in health care and, 73–5
 - in continuum of health system typologies, 222–5
 - in EU health law, 214–15, 537–8, 540–4
 - external health law and, 433–7
 - free movement of goods and services and, 194–8
 - health professionals and role of, 127–32, 154–5
 - hospital regulation and, 247–52
 - institutions and professions and, 247–65
 - laboratories regulations and, 259–61
 - organ and blood donation regulation and, 478–83
 - pharmacies regulation and, 252–9
 - questions and answers on, 554–5
 - substitutive private health insurance and, 237–40
 - systemic focus on healthcare and, 211–13
- Soskice, David, 222–5
- Source Informatics* case, 172–6
- Spain
 - austerity impact on healthcare in, 52–3
 - blood bank quality controls in, 101
 - patients’ rights in, 185–9
 - pharmacies regulation in, 252–9

- specialized health care
 - classification of, 127–32
 - patient mobility rights and, 198
- sponsors
 - Clinical Trials Directive guidelines for, 305–12
 - medical device and products regulation and, 371–8
- Stamatelaki* case, 202–6
- Standing Committee on Foodstuffs, 404–10
- Standing Committee on the Food Chain and Animal Health, 404–8
- ‘state aids law’
 - competition law and freedom to trade in EU health sector and, 229–35
 - hospital regulation and, 247–52
- stateless persons, social security entitlements
 - coordination with patients’ rights and, 189–94
- statute law, origins of health laws and, 13–17
- stem cells
 - Blood Safety Directive and, 349–52
 - citizens’ initiative concerning, 95n126
 - competition law and freedom to trade concerning, 229–35
 - EU regulation of, 322–4, 352–8
 - human rights constraints on, 170–6
 - organ donation and transplantation and, 472–83
- Stjernø, S., 214–15
- Stokes, Elen, 360–1
- ‘Strategy for Europe on Nutrition, Overweight and Obesity-related Health Issues’, 414–18
- strict liability, compensation for harm from pharmaceuticals and medical products and, 379–84
- ‘substantial safety hazard’ principle, patient mobility rights and, 198
- substitutive private health insurance,
 - competition and free movement law and, 237–40, 243–6
- ‘super-stewardship’, global health law and, 433–7
- ‘supplementary patent certificate’, 341–7
- supplementary private insurance, competition and free movement law and, 235–46
- supply and demand
 - cross-border movement of goods and services and, 101–5
 - medical tourism and, 437–43
 - organ donation and transplantation and, 478–83
- supremacy principle, internal market strategies for EU health law and, 34–40
- suspension of health professionals, 146–51
- Sweden, entry into health professions in, 142–6
- Swedish Match, 392–4
- systemic perspectives in healthcare law, 6–9, 540–4
 - freedom to trade across borders and, 227–9
 - future potential of, 546–8
- tax-financed national health systems, 220–1
 - competition and free movement law and, 235–43
 - patient mobility rights and, 76–83
 - substitutive private health insurance and, 237–40
- Technical Standards Directive 98/34/EC,
 - alcohol regulation and, 418–23
- temporary services, service providers and posted workers, 137–40
- Terrier, Dominique, 3–4
- terroir* principle, food regulation and, 403–4
- testing procedures, health law and, 26–7
- TGN1412 monoclonal antibody, 292–5
- Thalidomide disaster, 292–5
 - compensation for harm from pharmaceuticals and medical products and, 379–84
- ‘therapeutic cloning’, human rights constraints and, 170–6
- ‘therapeutic equivalence’ concept,
 - pharmaceuticals relations and, 270–8
- third-country nationals, right to health care for, 176–7
- third generation trade agreements, 462n108, 463–9
- threshold values, public procurement regulations and, 270–8
- tissue engineering
 - globalization of health research and, 504–8
 - Human Tissue and Cells Directive and, 352–8
- Titmuss, Richard, 478–83
- Tobacco Advertising and Sponsorship Directive (98/43/EC), 68–9, 390–403
- Tobacco Products Directive (2001/37/EC), 526–30

Tobacco Products Directive (2014/40/EU), 392–4, 399–403	travel, board and lodging reimbursement, cross-border health services regulations and, 78–82
tobacco regulation	treaty law
assessment of EU regulations, 423–4	cross-border movement of products and services, 100–5
CJEU case law and, 55–9	EU trade law and, 457–63
coherence in EU health law concerning, 45–50, 60–3	food laws and, 404–8
EU regulatory approaches to, 387–403	free movement of goods and services and, 194–8
global health and, 437–43, 522–30	health rights as human rights and, 156–60
harm reduction approach in, 399–403	international law and, 445–7
packaging regulations, 394–6	legislative and judicial procedures for health law and, 63–9
product regulation, 396–9	mainstreaming of EU health law and, 60–3
risk management and, 292–5	mainstreaming of health legislation and, 60–3
‘Together for Health’ (European Commission), 50–3, 156–60, 535–6	patient and consumer protection rules and, 112–18
tort law, evolution of health law and, 13–17	patient mobility rights and, 76–83, 194–8
Trade-Mark Directive (89/104/EEC), 108–12	right to health care and, 164–6
‘market pathway’ model for pharmaceuticals regulation and, 341–7	social security entitlements coordination with freedom of movement and, 189–94
Trade-Mark Directive (2008/95/EC), 341–7	Treaty on European Union (TEU)
trade-mark law	healthcare law and, 6–9
counterfeit/falsified medicines and, 492–8	legislative and judicial procedures for health law and, 63–9
exhaustion of, 108–12, 341–7	mainstreaming of health legislation and, 60–3
health care products market and, 108–12	obesity laws and, 414–18
‘market pathway’ model for pharmaceuticals regulation and, 341–7	Treaty on the Functioning of the European Union (TFEU)
trading rules, pharmacies regulations and, 252–9	access to healthcare and EU citizenship in, 202–6
transitional economies, medical tourism and, 437–43	Article 6, 160–4, 457–63
transnational trade, external health law and, 433–43	Article 9, 535–6
transparency	Article 30, 108–12, 252–9
internal market strategies for EU health law and, 34–40	Article 34, 105–8, 120–4
‘market pathway’ model for pharmaceuticals regulation and, 341–7	Article 36, 120–4
risk regulation and, 424–31	Article 45, 132–7
technology assessment and, 303n59	Article 49, 132–40, 252–61, 264–5
Transparency of Pharmaceuticals Pricing Directive (89/105/EEC), 108–12, 270–8	Article 54, 252–9
internal market strategies for EU health law and, 34–40	Article 56, 76–85, 88–91, 94–6, 137–40, 194–8, 199–202
‘market pathway’ model for pharmaceuticals regulation and, 341–7	Article 63, 252–9
technology assessment and, 303n59	Article 101, 262–4
transplantation. <i>See</i> organ donation and transplantation	Article 102, 281–5
transversal aspects of EU health law, 60–3	Article 106, 240, 247–52
public health policies and, 387–90	Article 107, 237–40
	Article 114, 85–8
	Article 168, 85–8, 457–63, 478–83, 535–6

- Treaty on the Functioning of the European Union (TFEU) (*cont.*)
Article 207, 457–63, 492–8
Article 208, 463–9
Article 218, 457–63
Article 258, 83–5
Article 267, 83–5
coherence in EU health law and, 40–53
EU trade law and, 457–63
free movement of goods and services in, 194–8, 199–202
health legislation and, 6–9, 53–5
intellectual property rules and, 108–12
legislative and judicial procedures for health law and, 63–9
mainstreaming of health legislation and, 60–3
‘market pathway’ model for pharmaceuticals regulation and, 341–7
patient mobility rights in, 76–83
risk regulation and, 295–301
social security entitlements coordination and, 199–202
‘TRIPS-plus’ agreements, intellectual property rights and, 486–92
Tuohy, Carolyn, 211–13, 219–21
TÜV-Rheinland, 3, 548–50
- Ubani, Daniel, 153–4
UK Human Rights Act 1998, 91–6
UK v. Commission (BSE), 60–3
unambiguous consent, data protection and privacy and, 170–6
UN Committee on Economic, Social, and Cultural Rights (UNESCR), global health and, 448–51
UN Conference on Trade and Development (UNCTAD), 463–9
UN Convention on the Rights of the Child, 176–7
‘undertakings’
 competition law and freedom to trade decisions and, 229–35
 free movement and competition laws and, 235–43
 hospital regulation and, 247–52
 substitutive private insurance as, v
‘undue delay’ in cross-border health care, 199–202
UNESCR, global health law and, 448–51
UN Human Genetics Advisory Commission (HGAC), 171n119
- UNITAID drug purchasing organization, 492–8
- United Kingdom
 BSE crisis in, 60–3, 65
 contract nurses from Spain in, 151–3
 Court of Appeal in, 55–9
 dental clinics regulations in, 262–4
 ‘development risks defence’ in damage compensation and, 379–84
 entry into health professions in, 142–6
 ethical sensitivity issues in, 91–6
 health rights law in, 160–4
 industry challenges to pricing restrictions in, 281–5
 medical device regulation in, 366–7
 Medicines Control Agency, 333–4
 organ transplants in India and, 473–7
 origins of health laws in, 13–17
 pharmaceuticals and medical device regulations in, 270–8
 pharmacies’ regulations in, 257–9
 pharmacy services and products regulations and, 120–4
 pricing challenges and generic promotion in, 278–81
 private health insurance in, 235–43
 regulation of health care in, 23–4
 Source Informatics case in, 172–6
 TFEU health mainstreaming and, 60–3
 tobacco packaging regulation in, 394–6
- United Nations, global health law and, 448–51
United Nations Charter, 508–11
- United States
 Medicaid and Medicare system in, 481–2
 migrant workers’ health rights in, 191n63
 priority review vouchers for medicinal product development in, 498–501
 risk regulation in, 298–301
- Universal Declaration of Human Rights, 156–60
 organ donation and transplantation and, 473–7
- USA Medical Devices Amendments, 366–7
- vaccines
 compensation for harm from, 380n244
 development funding for, 490–1
 ECDC initiatives for, 512–17
 market incentives for development of, 498–501
- Valeant Pharmaceuticals, 285–8

value-driven decision-making, risk regulation and, 295–301	World Bank, 437–43
<i>Vanbraekel</i> case, 78, 83–5, 199–202	health care policies of, 222–5
Vanhercke, Bart, 69–70	World Health Assembly, 448–51
<i>Van Riet</i> case, 199–202	organ donation and transplantation and, 473–7
VAT Directive, blood and human tissue centres and, 261–2	World Health Organization (WHO)
Viagra, CJEU case law on funding for, 55–9	blood and blood productis donation and, 478–83
Vienna Declaration on Nutrition and Non-communicable Diseases, 414–18	counterfeit/falsified medicines and, 492–8
Voluntary Health Association (India), 473–7	essential medicines list, 483–5
Voluntary Health Insurance Board (Ireland), 237–40	establishment of, 508–11
<i>von Chamier-Glisczinski</i> case, 202–6	EU food safety law and policy and, 517–22
Vos, Ellen, 517–22	EU health law and, 15–17
<i>Vo v. France</i> case, 22–3	European Centre for Communicable Disease Control and, 512–17
warning labels	global health law and, 448–51
on pharmaceuticals, 337–41	globalization of health research and, 508
on tobacco, 390–403	health indicators from, 67–8
tobacco packaging, 394–6	obesity issues and, 414–18
water, EU laws on, 523n152	patients’ rights and, 184–9
<i>Watts</i> case, 55–9, 75–6, 78, 199–202, 247–52	right to health provisions of, 156–60
welfare paradigms, competition and equality in health systems and, 227–9	World Intellectual Property Organization (WIPO), 496–8
Westerhäll, Lotte, 15–17	World Trade Organization (WTO), 437–43
Winslow, C.E.A., 387–90	Anti-Counterfeiting Trade Agreement and, 496–8
working conditions	Dispute Settlement bodies, 448–54
for healthcare workers, 60–3	EU trade law and, 457–63
health professionals and, 140–2, 151–3	food-related law and policy and, 523–6
Working Party on Herbal Medicinal Products, 333–4	global health and, 451–4
Working Time Directive (2003/88/EC), 140–2, 151–3, 538–40	intellectual property law harmonization and, 486–92
working time legislation, 140–2, 151–3, 538–40	International Health Regulations and, 508–11
	tobacco law and policy and, 526–30